US20020072780A1 - Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity - Google Patents

Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity Download PDF

Info

Publication number
US20020072780A1
US20020072780A1 US09/963,149 US96314901A US2002072780A1 US 20020072780 A1 US20020072780 A1 US 20020072780A1 US 96314901 A US96314901 A US 96314901A US 2002072780 A1 US2002072780 A1 US 2002072780A1
Authority
US
United States
Prior art keywords
stimulation
electrical
recited
gastric
stimulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/963,149
Inventor
Stephen Foley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Transneuronix Inc
Original Assignee
Transneuronix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transneuronix Inc filed Critical Transneuronix Inc
Priority to US09/963,149 priority Critical patent/US20020072780A1/en
Assigned to TRANSNEURONIX, INC. reassignment TRANSNEURONIX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOLEY, STEPHEN T.
Publication of US20020072780A1 publication Critical patent/US20020072780A1/en
Priority to US10/782,087 priority patent/US7941221B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/08Arrangements or circuits for monitoring, protecting, controlling or indicating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control

Definitions

  • the present invention relates to an implantable gastric electrical stimulator system that can be used to decrease gastric motility and/or gastric efficiency for the treatment of obesity. More particularly, the system employs an implantable electrical stimulator, one or a plurality of implantable stimulator leads (electrodes), and an external programmer, and an algorithm used to automatically control synchronized electrical stimulation frequency, interval, amplitude, or a combination of such parameters for treatment of obesity and other eating disorders.
  • Obesity is a major health concern in western civilization. Surveys indicate that 33% of the population is overweight with the number increasing every year. Obesity is the second leading cause of preventable death in the United States. It is associated with several comorbidities that affect almost every body system. Some of these comorbidities are: hypertension, diabetes, coronary disease, breathing disorders, and musculoskeletal problems. It is estimated that the costs associated with obesity approach $70 billion per year.
  • Gastroparesis is an adverse medical condition in which normal gastric function is impaired.
  • Gastroparetic patients exhibit reduced gastric motility with accompanying symptoms of nausea and/or vomiting and gastric discomfort. They may complain of bloating or a premature or extended feeling of fullness (satiety).
  • the condition results in reduced food intake (in portion and/or frequency) and subsequent weight loss.
  • the condition may be associated with damage or neuropathy of the stomach enervation or damage or dystrophy of the stomach muscle with subsequent attenuated (in amplitude and/or frequency) peristaltic activity of the stomach muscles.
  • the stomach is a complex organ of the digestive tract (alimentary canal) with the primary functions of dissolution, reduction, and motility of ingested food. These typical functions are accomplished through secretion of biochemical reagents to promote dissolution; kinetic mixing movements to reduce the particle size and promote mixing; and kinetic propulsive movements to move the chyme (solution of small food particles and biochemical reagents) into the intestines.
  • the kinetic movements of the stomach are accomplished by organized/phased contractions of the stomach wall/smooth muscle.
  • the neural control component refers to the intrinsic and extrinsic nerves innervating the stomach.
  • the intrinsic nerves release various neurotransmitters and peptides that control contractions and motility. Studies indicate that the extrinsic nerves may influence the contractions by the release of modulative substances.
  • the chemical control component refers to the various substances (neurotransmitters, neuromodulators and peptides) released from the nerve endings or endocrine-paracrine cells and glands of the stomach. These biochemical substances may act directly on the smooth muscle cell or on the nerves to modulate or control the occurrence of contractions and motility.
  • the myogenic control component refers to small electrical oscillations of the smooth muscle cells related to polarization and depolarization of the smooth muscle cells.
  • the myogenic activity is referred to as electrical control activity or slow waves.
  • the slow wave is the underlying clock for peristaltic activity.
  • Slow waves are omnipresent and typically occur at frequencies of 2-4 cycles per minute. All slow waves are not linked to contractions, but a normal peristaltic contraction must occur in synchrony with a slow wave.
  • the slow wave (resulting from the cell membrane potential depolarization) provides the basic timing/interval and organization.
  • the strength of the typical slow wave depolarization alone is not sufficient to exceed the excitation threshold required to initiate the smooth muscle contraction.
  • a neural or chemical component must also be present to augment the myogenic activity. When a neural and/or chemical component is present, the depolarization strength exceeds the excitation threshold and a contraction occurs. (The contraction results in additional electrical activity referred to as electrical response activity or action potentials.)
  • the contraction involves the circular and longitudinal muscle layers of the stomach wall. Contraction of the circular smooth muscle layer decreases the lumen diameter. Contraction of the longitudinal muscle layer decreases the length of the stomach and may serve to assist in expansion of the lumen adjacent to the contracted circular muscle layer and to propagate the contraction to the neighboring uncontracted segment of the circular muscle. Coordinated contraction between both muscle layers is necessary for peristaltic propagation.
  • interference may impair the contraction and its associated kinetic function.
  • the interference may be administered as any one or combination of the following:
  • Additional methodologies may also accomplish the same ends, but may not be as easily applied, may require iterative or multiple applications or may be difficult to reverse. These additional methods include:
  • Cigaina for “Process and Device for Treating Obesity and Syndromes Related to Motor Disorders of the Stomach of a Patient” issued Jun. 3, 1995, describes an implantable gastric electrical stimulator at the antrum area of the stomach which generates sequential electrical pulses to stimulate the entire stomach, thereby artificially altering the natural gastric motility to prevent emptying or to slow down food transit through the stomach.
  • Cigaina however has the inherent disadvantage that it is a stimulation device solely, and does not incorporate on-demand stimulation other than that of manual cycling provided by magnetic application, which wastes energy by applying stimulation when it is not therapeutically required.
  • Chen et al. additionally provides a sensor electrode or a stimulation electrode wherein the response of an organ to an electrical stimulation pulse is sensed for delivering stimulation to a plurality of electrodes to provide phased electrical stimulation.
  • Chen et al. is specifically directed to phased stimulation that progresses through the plurality of electrodes located along the peristaltic flow path and specifically senses the response of the organ to the electrical stimulation. Chen does not address sensing of the intrinsic electrical activity for the purpose of applying therapy.
  • the Bourgeois sensing circuitry inhibits therapy if a peristaltic wave is sensed and provides stimulation if it is not sensed. It does not apply therapy to impair gastric motility.
  • U.S. Pat. No. 6,091,992 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Jul. 18, 2000, is similar to the '994 patent. It relates to provision of separate electrical pulse trains of differing parameters wherein the pulse trains are composed of a series of at least two pulses. The therapy is applied to promote gastric peristalsis.
  • '955 addresses stimulation to promote gastric normalcy.
  • the known prior art relates to (1) the provision of electrical stimulation (phased or unphased) without regard to intrinsic activity, or (2) the provision of electrical stimulation to induce normal peristalsis, or (3) the provision of electrical stimulation to counteract abnormal gastric activity.
  • the present invention is directed to applying an implantable gastric stimulation (IGS) and lead system to sense intrinsic gastric electrical activity, identify that activity as normal or abnormal, and to apply electrical stimulation to the normal activity for the intended purpose of disrupting/disorganizing it.
  • IGS implantable gastric stimulation
  • lead system to sense intrinsic gastric electrical activity, identify that activity as normal or abnormal, and to apply electrical stimulation to the normal activity for the intended purpose of disrupting/disorganizing it.
  • the present invention relates to a gastric simulator system and method for gastric stimulation of a patient employing an implantable gastric stimulator, which includes an information processor, electrical stimulation circuitry, electrical sensing circuitry, electrode switching circuitry, and telemetry circuitry.
  • a remote programmer is provided to operate with the telemetry circuit of the implantable gastric stimulator for controlling the operation of the electrical stimulator circuit with the information processor.
  • Leads are provided between the implantable gastric stimulator and the stomach wall of the patient for stimulation and/or sensing electrodes.
  • the stimulation electrodes are provided for conveying electrical signals from the electrical stimulator circuit to the stomach wall of the patient, while the sensor electrodes are provided for communicating intrinsic gastric electrical activity information (from the stomach wall of the patient) via the electrical sensing circuitry to the information processor.
  • the electrode switching circuitry allows the function and polarity of each electrode to be controlled by the information processor.
  • FIG. 1 illustrates the components of the IGS system
  • FIGS. 2A and 2B further illustrate the stimulation lead and the construction of the lead body
  • FIG. 3 shows the placement of the electrodes in the stomach
  • FIG. 4 shows a functional block diagram of a single channel IGS
  • FIG. 5 shows a functional block diagram of a multi-channel
  • FIG. 6 illustrates possible sensing “pairs” and stimulation vectors (“pairs”) of electrodes for a three electrode system
  • FIG. 7 illustrates possible sensing “pairs” and stimulation vectors for a four electrode system
  • FIG. 8 illustrates the progression of a normal gastric slow wave along the stomach
  • FIG. 9 depicts the discernible features of a gastric slow wave
  • FIG. 10 illustrates identification/classification of normal and abnormal gastric activity
  • FIG. 11 depicts electrical stimulation at multiple sites
  • FIG. 12 depicts electrical stimulation across a slow wave
  • FIG. 13 depicts electrical stimulation with a spatial offset
  • FIG. 14 depicts electrical stimulation with a spatial and temporal offset
  • FIG. 15 depicts anticipatory electrical stimulation
  • FIG. 16 illustrates the sensing history used to calculate the anticipated interval of the next slow wave
  • FIG. 17 illustrates the timing of the anticipatory stimulation
  • FIG. 18 illustrates decoupling stimulation (triggered by sensing at position C) applied at position E.
  • the decoupling stimulus is intended to initiate an opposing contraction
  • FIG. 19 illustrates proportional stimulation intended to disorganize 25% of the normal slow waves
  • FIG. 20 illustrates proportional stimulation intended to disorganize 50% of the normal slow waves. An alternative embodiment would disrupt every other normal slow wave.
  • the preferred embodiment of the invention consists of an implantable gastric stimulator (IGS), one or a plurality of implantable leads (two or more electrodes) that are electrically coupled to the stomach wall and the IGS, and an external programmer which can non-invasively communicate (bi-directionally) with the IGS via a radio frequency data link (see FIG. 1).
  • IGS implantable gastric stimulator
  • implantable leads two or more electrodes
  • an external programmer which can non-invasively communicate (bi-directionally) with the IGS via a radio frequency data link (see FIG. 1).
  • the external programmer is the interface between the physician (user) and the IGS. It consists of a transceiver to communicate with the IGS, a user interface (e.g., keyboard, tactile or soft buttons, display, and software) to provide a usable input/output method to the physician, and electronic circuitry and software to process the inputs or outputs to the appropriate format for either end (device or user).
  • the programmer conveys information to the device and receives information from the device via a radio frequency data link. The information is conveyed as a string of data packets. In the preferred embodiment, an error checking algorithm would be utilized to determine the veracity of the string or packet.
  • the implantable lead consists of a connector (proximal) end that interfaces (electrically and mechanically) to the IGS, a lead body (medial portion) that is electrically continuous between the connector (proximal) electrical terminals and the electrodes, and an electrode (distal) end that interfaces with the stomach wall (reference FIG. 2A).
  • the connector end consists of one or a plurality of proximal electrical terminations, a means for insulation between the terminations and between the terminations and the surrounding environment, and a mechanical means for securing the connector to the IGS connection.
  • the lead body (medial portion) consists of an electrically continuous path between the electrode(s) and proximal electrical terminations.
  • the path is an elongated metallic coil.
  • the lead body can have one or a plurality of coils. The coils are insulated from each other and from the surrounding environment by an insulating sheath(s).
  • FIG. 2B depicts a typical lead body construction. Typically, each coil is connected to a specific proximal terminal (corresponding to an IGS input/output) and a specific electrode. An alternative configuration may have multiple electrodes connected to the same coil.
  • the electrode (distal) end of the lead communicates electrically to the stomach wall.
  • the electrodes are utilized in pairs to perform bipolar sensing and stimulation.
  • the bipolar pairs are not required to be resident on the same implantable lead (multiple monopolar leads or a combination of monopolar and multipolar leads may be used instead).
  • the electrodes should communicate with the circular layer of the stomach smooth muscle. This communication can be effected by superficial contact with the serosa, embedding the electrode intramuscularly (within the longitudinal or circular muscle), or by sub serosal placement.
  • FIG. 3 depicts the electrodes embedded within the circular layer. The electrode size and configuration must consider the function, the implantation location, and the stimulation parameters to be utilized.
  • a sensing electrode should have maximum surface area to acquire the intrinsic electrical signal.
  • a stimulation electrode should have minimal surface area to concentrate the energy density for stimulation, but must also consider the effects of dissociation of the metal due to the stimulation pulse and due to ion imbalance.
  • the gastric wall varies in thickness (depending on location) from 4-5 mm to greater than 1 cm with the circular and longitudinal layers comprising approximately half that thickness.
  • the distal end contains the means for securely attaching the electrodes to the gastric wall.
  • the fixation mechanism of the preferred embodiment is a pair of polymer tines that oppose each other and are located on either side of the electrode(s).
  • FIG. 2A depicts the tine configuration at the distal end of the lead.
  • An alternative fixation embodiment is to secure the lead to the gastric wall with a suture through the tissue and around an elastomer sleeve on the lead body.
  • the IGS is a small, compact pulse generator. Externally, it consists of a hermetic housing and a means for electrically and mechanically connecting the lead to the internal electronics. Internally, the IGS contains electronic circuitry and a power supply (battery and/or rf energy coupling circuitry).
  • the electronic circuitry consists of a microprocessor, electrical sensing (input) circuitry, electrical stimulation (output) circuitry, electrode switching circuitry, telemetry circuitry, and random access memory (reference FIG. 4).
  • the IGS may have multiple sensing and/or stimulation circuits (channels) to provide more optimum sensing and stimulation to differing areas of the gastric system (reference FIG. 5).
  • the microprocessor is an integrated circuit that serves as an information processor that controls the IGS functions, performance, and analyses (if any). It receives inputs from the telemetry circuitry, the sensing circuitry, the RAM, and from internal functional checking. Depending upon the programming and the inputs, the microprocessor controls outputs to the telemetry circuitry, the stimulation circuitry, the RAM, and the electrode switching circuitry. The processor controls the basic timing and routing of the inputs and the output sequencing and parameters.
  • the sensing circuitry receives signals from the intrinsic gastric electrical activity via the selected sensing electrodes of the lead(s).
  • the sensing input is utilized to classify the intrinsic gastric activity and as the trigger for the stimulation output.
  • the sensing circuitry filters and amplifies the intrinsic signal and conveys it to the microprocessor.
  • the sensing circuitry may employ a neural network approach to assist in the classification of the intrinsic gastric activity.
  • the selection of the sensing electrodes, the timing of the sensing, and degree of amplification is controlled by the microprocessor and is programmable (via the telemetry circuitry).
  • the stimulation circuitry provides the electrical pulses employed for stimulation.
  • the stimulation circuitry may invoke either a constant current approach or a constant voltage approach.
  • the stimulation circuitry will provide pulses of programmable amplitude, frequency (pulses per second), and pulse width.
  • An alternative embodiment entails the use of switching between individual capacitors in an array (switch cap technology) to provide adjacent or overlapping pulses of narrow width to achieve a continuous (or near continuous) pulse of a wider width.
  • the stimulation circuitry is controlled by the microprocessor and is programmable.
  • the electrode switching circuitry establishes the function of each electrode and the polarity of the electrode.
  • the electrode switching circuitry will enable a pair of electrodes to be used for sensing, and a pair or pairs of electrodes to be used for stimulation.
  • FIGS. 6 and 7 depict possible sensing configurations (“pairs”) and possible stimulation vectors for a three and a four electrode system. The stimulation and sensing may utilize the same electrodes.
  • the electrode switching circuitry can change the polarity of the stimulation electrodes to create multi-phasic pulses, alternating polarity between pulses or a series of pulses, and different stimulation vectors.
  • the switching circuitry can enable different pairs of sensing electrodes to sample gastric electrical activity at various sensing locations or along different vectors. Complex sensing patterns can be invoked to differentiate slow wave propagation direction and intervals. The switching circuitry may also include compensation (to offset internal leakage currents across the switches involved in sensing) and blanking to prevent stimulation pulses from saturating the sense amplifiers.
  • the switching circuitry is controlled by the microprocessor and is programmable. Complex switching schemes can be stored in RAM and be activated as a program. The switching software would be designed to ensure that each configuration would have at least one bipolar pair to complete the electrical circuit.
  • the telemetry circuitry consists of an antenna and a transceiver.
  • the circuitry may also include a telemetry buffer to accommodate large data transactions.
  • the telemetry circuit transmits and receives pulses to and from the programmer.
  • the circuitry may employ amplitude modulation, frequency modulation, or pulsed modulation at radio frequencies.
  • the telemetry would have a range of several inches to allow for deep implantation of the IGS.
  • the telemetry string would utilize an initiation protocol to establish two way communication, an identity packet to provide device/programmer identification, multiple information or programming packets to communicate the requisite data, error checking of the packets (cyclic redundancy checking or check sums) to ensure accuracy of the information, and a termination protocol to signal the end of the string.
  • the incoming string would be processed by the microprocessor to set the parameters of the IGS.
  • the outgoing string would basically acknowledge that the incoming string was accepted, confirm IGS settings or provide raw data/information for processing by the external programmer.
  • the RAM is used to store information and programs for the IGS.
  • the RAM receives the sensed information about the intrinsic gastric activity from the microprocessor, analyzes that information to determine if the activity is normal according to a selected algorithm(s), and provides that analysis output to the microprocessor to initiate the therapy in accordance with the particular programming selected.
  • Multiple programs may be stored in RAM to establish specific profiles of IGS activation, response, and performance.
  • the RAM may also be used to store various parameters that indicate device performance, gastric activities, and therapies administered.
  • the electrodes of the lead(s) would be implanted (laparoscopically or through an open incision) in or on the gastric wall for communication with the circular layer of the gastric smooth muscle (reference FIG. 3). Since the lower portion of the stomach is primarily responsible for solids mixing and motility, the preferred location of the electrodes is the antrum, along the lesser curvature. The lesser curvature is preferable because it does not distend as much as the greater curvature and offers a more stable position. After the lead is secured, the IGS would be connected to the lead(s) and implanted in a subcutaneous or sub-fascial pocket in the patient's abdomen.
  • FIG. 8 depicts the progression of a normal slow wave along the stomach from position A through position F.
  • the normal activity has pulse amplitudes, pulse widths, and frequency (intervals) that are discernible from abnormal activity.
  • FIG. 9 depicts the discernible parameters that can be utilized to identify/classify the slow wave.
  • the depolarization of the cells will impart an electrical potential on that electrode (differentially compared to a second electrode in an area not undergoing depolarization). If the two electrodes have been programmed to serve as sensing electrodes, the electric potential is conveyed to the sensing circuitry. There it is filtered and amplified and presented to the information processor.
  • the information processor (in conjunction with any RAM program/algorithm) identifies/classifies the activity as normal or abnormal.
  • FIG. 10 depicts a string of gastric activity and the potential classification of the waves. If identified as normal, the information processor initiates stimulation as per the programmed parameters. If classified as abnormal, the microprocessor re-initiates sensing. Certain parameters of the intrinsic signal and stimulation are logged into RAM for history and for use in other algorithms.
  • An alternative embodiment of the invention analyzes the frequency components of the sensed signal for evidence of electrical response activity resulting from a contraction. If the signal contains frequencies that are associated with a contraction, a stronger type of stimulation is invoked to disrupt/disorganize or decouple the contraction.
  • the preferred embodiment may invoke one or multiple stimulation therapies that are dependent upon the activity sensed and the programmed therapeutic scheme.
  • the stimulation may use electrical pulse trains of equally alternating polarity, electrical pulse trains of asymmetrically alternating polarity, and multiphasic pulses of equal or unequal phase widths.
  • the stimulation may be delivered at a single or a plurality of sites.
  • FIG. 11 depicts stimulation at multiple (two) sites. Additionally the stimulation vector can be switched (at any point) between any single pair of electrodes or plurality of electrodes providing that at least one bipolar pair is selected (reference FIGS. 6 and 7).
  • the stimulation schemes are described as follows:
  • Stimulation across a slow wave occurs when the stimulation is applied between electrodes that lie on opposite sides of the slow wave. It is designed to depolarize cells prior to the wave induced depolarization. This will make the cells refractory to the wave and create an attenuation of the slow wave in the area of stimulation. Stimulation across the wave has a disadvantage in that some of the cells involved are already depolarized (as a result of the wave) and energy is wasted on those cells.
  • Stimulation in advance (spatial offset) of propagation affords the advantage of only involving cells that are not part of the wave.
  • the disadvantage is that the degree (length and direction/orientation) of the spatial offset must be considered to ensure that cell repolarization does not occur before the wave arrives. It may require relatively fixed configurations of electrodes placed in relation to the propagation path.
  • Stimulation in advance (spatial and temporal offsets) of propagation (FIG. 14).
  • Stimulation in advance of wave propagation with a temporal and a spatial offset involves sensing at one location and stimulation at a second location with a programmable delay to ensure that the cells do not repolarize before the wave arrives. It affords the advantage of a spatial offset and does not require precise electrode orientations to achieve the same ends.
  • Anticipatory stimulation involves sensing between a pair of electrodes and delaying the stimulation until just prior to the next normal wave is anticipated.
  • the stimulation may be applied to the sensing electrodes or any set of electrodes upstream from the sensing electrodes.
  • the amount of delay is calculated from the history of normal intervals derived from the sensing identification and parameter storage.
  • FIG. 16 depicts a running history used to calculate the expected interval timing until the next normal slow wave. The calculation would involve averaging a running history of normal intervals and subtracting a small time interval from that average.
  • FIG. 17 depicts the anticipatory stimulation interval timing.
  • Decoupling stimulation involves sensing a peristaltic contraction at one location and strong stimulation at a second location to invoke a competing contraction that would propagate towards and away from the intrinsic contraction. Where the two contractions meet, they would tend to cancel each other. The advancing invoked contraction would not have the volume of chyme because it would precede the intrinsic movement and the efficiency of the gastric motility would be reduced.
  • Ectopic stimulation involves overriding the intrinsic electrical activity by application of strong stimulation at an interval that is shorter than the intrinsic interval and at a location that does not afford a natural progression of the motility. The preferred location is on the gastric antrum close to the pylorus such that the majority of any propagation would be retrograde.
  • Combined nerve and gastric stimulation involves application of any of the previously listed therapy schemes with specific stimulation intended to suppress, block, or desensitize the enervation of the stomach.
  • the stimulation could be a combination of pulse trains having neuro and muscular components or separate channels dedicated to the specific neural or muscular waveforms.
  • Proportional stimulation is a modulator of any or all of the previous stimulation schemes (except ectopic stimulation).
  • proportional stimulation the disruptive, disorganizing, or decoupling stimulation is applied to a programmable percentage of the qualifying (normal) intrinsic activity.
  • FIGS. 19 and 20 depict disorganization of 25% and 50% of the normal slow waves. (An alternative embodiment of FIG. 20 is disorganization of every other normal slow wave.) This type of stimulation allows the physician to modulate the intrinsic activity and still preserve some normal function.
  • proportional stimulation will be less frequent due to the decreased quantity of qualifying normal waves.

Abstract

A sensor based gastric stimulator system and method for gastric stimulation of a patient employing an implantable gastric stimulator, which includes an information processor, an electrical stimulator circuit, and telemetry circuitry. The implantable stimulator senses intrinsic, gastric electrical activity (slow waves and/or peristaltic waves) and delivers electrical stimulation to intentionally disrupt or disorganize that activity. The stimulation is triggered by (tracks) normal gastric electrical activity and can be delivered with a spatial offset to anticipate the propagating gastric electrical activity or may be delayed temporally to anticipate the next propagating slow or peristaltic wave. The stimulator may be programmed to disrupt/disorganize all or a percentage of the intrinsic, normal gastric electrical activity. The programmer (via radio frequency data link) may non-invasively program stimulation parameters and intervals. The stimulator may provide stimulation to one or a plurality of stimulation sites and may incorporate one or a plurality of independently programmable sensing and/or stimulation channels. The information processor of the implantable gastric stimulator uses the gastric stimulation information from the non-electrode sensor for determining periods or windows of susceptibility for application of the electrical signals conveyed with the stimulation electrode for conveying electrical signals from the electrical stimulator circuit to the stomach wall of the patient.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application claims benefit of U.S. Provisional Application No. 60/235,660, filed Sep. 26, 2000.[0001]
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0002]
  • The present invention relates to an implantable gastric electrical stimulator system that can be used to decrease gastric motility and/or gastric efficiency for the treatment of obesity. More particularly, the system employs an implantable electrical stimulator, one or a plurality of implantable stimulator leads (electrodes), and an external programmer, and an algorithm used to automatically control synchronized electrical stimulation frequency, interval, amplitude, or a combination of such parameters for treatment of obesity and other eating disorders. [0003]
  • 2. Description of the Related Art [0004]
  • Obesity is a major health concern in western civilization. Surveys indicate that 33% of the population is overweight with the number increasing every year. Obesity is the second leading cause of preventable death in the United States. It is associated with several comorbidities that affect almost every body system. Some of these comorbidities are: hypertension, diabetes, coronary disease, breathing disorders, and musculoskeletal problems. It is estimated that the costs associated with obesity approach $70 billion per year. [0005]
  • Multiple factors contribute to obesity, but the two major factors are physical inactivity and overeating. Existing therapies include diet, exercise, appetite suppressive drugs, metabolism enhancing drugs, surgical restriction of the gastric tract, and surgical modification of the gastric tract. Efficacy of these therapies range from little or no weight loss up to weight loss approaching 50% of initial body weight. [0006]
  • Gastroparesis is an adverse medical condition in which normal gastric function is impaired. Gastroparetic patients exhibit reduced gastric motility with accompanying symptoms of nausea and/or vomiting and gastric discomfort. They may complain of bloating or a premature or extended feeling of fullness (satiety). Typically, the condition results in reduced food intake (in portion and/or frequency) and subsequent weight loss. Physiologically, the condition may be associated with damage or neuropathy of the stomach enervation or damage or dystrophy of the stomach muscle with subsequent attenuated (in amplitude and/or frequency) peristaltic activity of the stomach muscles. Some studies indicate that it is also associated with dysrhythmias of the stomach. [0007]
  • An examination of the symptomology and consequences of gastroparesis reveals some effects that could be beneficial as a therapy for obesity, if they could be mediated and modulated. This disclosure sets forth a class of implantable electrical device(s) that can potentially effect a mild, reversible form of gastroparesis by inducing electrophysiological disorganization or disruption in the normal stomach motility. [0008]
  • The stomach is a complex organ of the digestive tract (alimentary canal) with the primary functions of dissolution, reduction, and motility of ingested food. These typical functions are accomplished through secretion of biochemical reagents to promote dissolution; kinetic mixing movements to reduce the particle size and promote mixing; and kinetic propulsive movements to move the chyme (solution of small food particles and biochemical reagents) into the intestines. The kinetic movements of the stomach are accomplished by organized/phased contractions of the stomach wall/smooth muscle. [0009]
  • Normal contractions of the stomach are the result of three control components: neural activity, chemical activity, and myogenic activity. [0010]
  • The neural control component refers to the intrinsic and extrinsic nerves innervating the stomach. The intrinsic nerves release various neurotransmitters and peptides that control contractions and motility. Studies indicate that the extrinsic nerves may influence the contractions by the release of modulative substances. [0011]
  • The chemical control component refers to the various substances (neurotransmitters, neuromodulators and peptides) released from the nerve endings or endocrine-paracrine cells and glands of the stomach. These biochemical substances may act directly on the smooth muscle cell or on the nerves to modulate or control the occurrence of contractions and motility. [0012]
  • The myogenic control component refers to small electrical oscillations of the smooth muscle cells related to polarization and depolarization of the smooth muscle cells. The myogenic activity is referred to as electrical control activity or slow waves. [0013]
  • The slow wave is the underlying clock for peristaltic activity. Slow waves are omnipresent and typically occur at frequencies of 2-4 cycles per minute. All slow waves are not linked to contractions, but a normal peristaltic contraction must occur in synchrony with a slow wave. [0014]
  • To initiate normal peristaltic contractions, multiple control means must be present. The slow wave (resulting from the cell membrane potential depolarization) provides the basic timing/interval and organization. However, the strength of the typical slow wave depolarization alone is not sufficient to exceed the excitation threshold required to initiate the smooth muscle contraction. A neural or chemical component must also be present to augment the myogenic activity. When a neural and/or chemical component is present, the depolarization strength exceeds the excitation threshold and a contraction occurs. (The contraction results in additional electrical activity referred to as electrical response activity or action potentials.) [0015]
  • However, initiating the contraction is only part of the peristaltic activity. To be physiologically effective (efficiently reduce, mix and/or propulse the stomach contents), the contraction must propagate in an organized, phased manner in three dimensions and in time (across and/or along the various muscle layers of the stomach). [0016]
  • Typically, the contraction involves the circular and longitudinal muscle layers of the stomach wall. Contraction of the circular smooth muscle layer decreases the lumen diameter. Contraction of the longitudinal muscle layer decreases the length of the stomach and may serve to assist in expansion of the lumen adjacent to the contracted circular muscle layer and to propagate the contraction to the neighboring uncontracted segment of the circular muscle. Coordinated contraction between both muscle layers is necessary for peristaltic propagation. [0017]
  • Intentional interference with any or all of the three control components and/or the coordination of the contraction propagation may impair the contraction and its associated kinetic function. Electrophysiologically, the interference may be administered as any one or combination of the following: [0018]
  • (a) electrical stimulation that induces asynchronous depolarization of individual cells or small groups of cells just prior to (spatially or temporally) or during a slow wave or peristaltic wave creating disorganization/attenuation of the wave; [0019]
  • (b) electrical stimulation that induces synchronous depolarization of a large area of cells prior to a slow wave or peristaltic wave creating an area that is refractory to the wave (may also induce a contraction); [0020]
  • (c) persistent electrical stimulation of the stomach nerves creating a neural desensitization, suppression or blocking of the stimulated area; [0021]
  • (d) electrical stimulation that entrains the slow wave at a frequency greater than 4 cpm creating a tachygastria condition so that peristalsis does not occur; [0022]
  • (e) electrical stimulation that entrains the slow wave at a frequency that competes with the intrinsic frequency but originates at a different location(s) creating competing ectopic waves; and [0023]
  • (f) temporally or spatially segregated, directional electrical stimulation of the individual muscle layers creating decoupling of the peristaltic coordination. [0024]
  • Additional methodologies may also accomplish the same ends, but may not be as easily applied, may require iterative or multiple applications or may be difficult to reverse. These additional methods include: [0025]
  • (a) creation of gastric smooth muscle lesions by ablative techniques (radio frequency, microwave, cryogenic) to lessen the contractility of the muscle or to change the contraction vector to a less efficient direction/sequence; and [0026]
  • (b) administration of precise doses and patterns of intra-muscular paralytic agents (e.g., botulism toxin, curare, etc.) to prevent the affected areas from contracting and/or to force a contraction along a specific less efficient path. [0027]
  • These items are discussed in separate disclosures. This disclosure will focus on the electrophysiological means of impairment. [0028]
  • Electrical stimulation of the stomach and other portions of the gastric intestinal tract has been experimented with for some time. Most of the experimentation has been oriented toward improving the gastric emptying usually by attempting to speed up or strengthen/reinforce the peristaltic activity. [0029]
  • U.S. Pat. No. 5,423,872 to Cigaina for “Process and Device for Treating Obesity and Syndromes Related to Motor Disorders of the Stomach of a Patient” issued Jun. 3, 1995, describes an implantable gastric electrical stimulator at the antrum area of the stomach which generates sequential electrical pulses to stimulate the entire stomach, thereby artificially altering the natural gastric motility to prevent emptying or to slow down food transit through the stomach. Cigaina however has the inherent disadvantage that it is a stimulation device solely, and does not incorporate on-demand stimulation other than that of manual cycling provided by magnetic application, which wastes energy by applying stimulation when it is not therapeutically required. [0030]
  • U.S. Pat. No. 5,690,691 to Chen et al. for “Gastro-intestinal Pacemaker Having Phased Multi-Point Stimulation” issued Nov. 25, 1997, describes a portable or implantable gastric pacemaker employing a number of electrodes along the greater curvature of the stomach for delivering phased electrical stimulation at different locations to accelerate or attenuate peristaltic movement in the GI tract. Chen et al. additionally provides a sensor electrode or a stimulation electrode wherein the response of an organ to an electrical stimulation pulse is sensed for delivering stimulation to a plurality of electrodes to provide phased electrical stimulation. However, Chen et al. is specifically directed to phased stimulation that progresses through the plurality of electrodes located along the peristaltic flow path and specifically senses the response of the organ to the electrical stimulation. Chen does not address sensing of the intrinsic electrical activity for the purpose of applying therapy. [0031]
  • U.S. Pat. No. 5,836,994 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Nov. 17, 1998, describes an implantable gastric stimulator which incorporates direct sensing of the intrinsic gastric electrical activity by one or more sensors of predetermined frequency bandwidth for application or cessation of stimulation based on the amount of sensed activity. The Bourgeois sensing circuitry inhibits therapy if a peristaltic wave is sensed and provides stimulation if it is not sensed. It does not apply therapy to impair gastric motility. [0032]
  • U.S. Pat. No. 6,091,992 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Jul. 18, 2000, is similar to the '994 patent. It relates to provision of separate electrical pulse trains of differing parameters wherein the pulse trains are composed of a series of at least two pulses. The therapy is applied to promote gastric peristalsis. [0033]
  • U.S. Pat. No. 6,104,955 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Aug. 15, 2000, relates to a gastric stimulator with reversion to a sensing mode to determine the intrinsic slow wave interval to prevent stimulation when the gastric tract is in inter-digestive phases. Like the previous Bourgeois patents, '955 addresses stimulation to promote gastric normalcy. [0034]
  • U.S. Pat. No. 5,861,014 to Familoni for “Method and Apparatus for Sensing a Stimulating Gastrointestinal Tract On-Demand” issued Jan. 19, 1999, relates to an implantable gastric stimulator for sensing abnormal electrical activity of the gastrointestinal tract so as to provide electrical stimulation for a preset time period or for the duration of the abnormal electrical activity to treat gastric rhythm abnormalities. Familoni also addresses recording of abnormal activity for a preset time period, but does not address altering of a normal gastric activity to achieve a variable result such as treatment for obesity. It does not apply therapy to disrupt normal gastric activity. [0035]
  • Accordingly, the known prior art relates to (1) the provision of electrical stimulation (phased or unphased) without regard to intrinsic activity, or (2) the provision of electrical stimulation to induce normal peristalsis, or (3) the provision of electrical stimulation to counteract abnormal gastric activity. [0036]
  • Thus, the prior art does not address the provision of electrical stimulation with regards to intrinsic gastric electrical activity for the intended purpose of disrupting normal, intrinsic gastric activity. [0037]
  • SUMMARY OF THE INVENTION
  • The present invention is directed to applying an implantable gastric stimulation (IGS) and lead system to sense intrinsic gastric electrical activity, identify that activity as normal or abnormal, and to apply electrical stimulation to the normal activity for the intended purpose of disrupting/disorganizing it. [0038]
  • Briefly summarized, the present invention relates to a gastric simulator system and method for gastric stimulation of a patient employing an implantable gastric stimulator, which includes an information processor, electrical stimulation circuitry, electrical sensing circuitry, electrode switching circuitry, and telemetry circuitry. A remote programmer is provided to operate with the telemetry circuit of the implantable gastric stimulator for controlling the operation of the electrical stimulator circuit with the information processor. Leads are provided between the implantable gastric stimulator and the stomach wall of the patient for stimulation and/or sensing electrodes. The stimulation electrodes are provided for conveying electrical signals from the electrical stimulator circuit to the stomach wall of the patient, while the sensor electrodes are provided for communicating intrinsic gastric electrical activity information (from the stomach wall of the patient) via the electrical sensing circuitry to the information processor. The electrode switching circuitry allows the function and polarity of each electrode to be controlled by the information processor. [0039]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the components of the IGS system; [0040]
  • FIGS. 2A and 2B further illustrate the stimulation lead and the construction of the lead body; [0041]
  • FIG. 3 shows the placement of the electrodes in the stomach; [0042]
  • FIG. 4 shows a functional block diagram of a single channel IGS; [0043]
  • FIG. 5 shows a functional block diagram of a multi-channel; [0044]
  • FIG. 6 illustrates possible sensing “pairs” and stimulation vectors (“pairs”) of electrodes for a three electrode system; [0045]
  • FIG. 7 illustrates possible sensing “pairs” and stimulation vectors for a four electrode system; [0046]
  • FIG. 8 illustrates the progression of a normal gastric slow wave along the stomach; [0047]
  • FIG. 9 depicts the discernible features of a gastric slow wave; [0048]
  • FIG. 10 illustrates identification/classification of normal and abnormal gastric activity; [0049]
  • FIG. 11 depicts electrical stimulation at multiple sites; [0050]
  • FIG. 12 depicts electrical stimulation across a slow wave; [0051]
  • FIG. 13 depicts electrical stimulation with a spatial offset; [0052]
  • FIG. 14 depicts electrical stimulation with a spatial and temporal offset; [0053]
  • FIG. 15 depicts anticipatory electrical stimulation; [0054]
  • FIG. 16 illustrates the sensing history used to calculate the anticipated interval of the next slow wave; [0055]
  • FIG. 17 illustrates the timing of the anticipatory stimulation; [0056]
  • FIG. 18 illustrates decoupling stimulation (triggered by sensing at position C) applied at position E. The decoupling stimulus is intended to initiate an opposing contraction; [0057]
  • FIG. 19 illustrates proportional stimulation intended to disorganize 25% of the normal slow waves; and [0058]
  • FIG. 20 illustrates proportional stimulation intended to disorganize 50% of the normal slow waves. An alternative embodiment would disrupt every other normal slow wave.[0059]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The preferred embodiment of the invention consists of an implantable gastric stimulator (IGS), one or a plurality of implantable leads (two or more electrodes) that are electrically coupled to the stomach wall and the IGS, and an external programmer which can non-invasively communicate (bi-directionally) with the IGS via a radio frequency data link (see FIG. 1). [0060]
  • The external programmer is the interface between the physician (user) and the IGS. It consists of a transceiver to communicate with the IGS, a user interface (e.g., keyboard, tactile or soft buttons, display, and software) to provide a usable input/output method to the physician, and electronic circuitry and software to process the inputs or outputs to the appropriate format for either end (device or user). The programmer conveys information to the device and receives information from the device via a radio frequency data link. The information is conveyed as a string of data packets. In the preferred embodiment, an error checking algorithm would be utilized to determine the veracity of the string or packet. [0061]
  • The implantable lead consists of a connector (proximal) end that interfaces (electrically and mechanically) to the IGS, a lead body (medial portion) that is electrically continuous between the connector (proximal) electrical terminals and the electrodes, and an electrode (distal) end that interfaces with the stomach wall (reference FIG. 2A). [0062]
  • The connector end consists of one or a plurality of proximal electrical terminations, a means for insulation between the terminations and between the terminations and the surrounding environment, and a mechanical means for securing the connector to the IGS connection. [0063]
  • The lead body (medial portion) consists of an electrically continuous path between the electrode(s) and proximal electrical terminations. Typically, the path is an elongated metallic coil. The lead body can have one or a plurality of coils. The coils are insulated from each other and from the surrounding environment by an insulating sheath(s). FIG. 2B depicts a typical lead body construction. Typically, each coil is connected to a specific proximal terminal (corresponding to an IGS input/output) and a specific electrode. An alternative configuration may have multiple electrodes connected to the same coil. [0064]
  • The electrode (distal) end of the lead communicates electrically to the stomach wall. In the preferred embodiment, the electrodes are utilized in pairs to perform bipolar sensing and stimulation. However, also in the preferred embodiment, the bipolar pairs are not required to be resident on the same implantable lead (multiple monopolar leads or a combination of monopolar and multipolar leads may be used instead). The electrodes should communicate with the circular layer of the stomach smooth muscle. This communication can be effected by superficial contact with the serosa, embedding the electrode intramuscularly (within the longitudinal or circular muscle), or by sub serosal placement. FIG. 3 depicts the electrodes embedded within the circular layer. The electrode size and configuration must consider the function, the implantation location, and the stimulation parameters to be utilized. A sensing electrode should have maximum surface area to acquire the intrinsic electrical signal. A stimulation electrode should have minimal surface area to concentrate the energy density for stimulation, but must also consider the effects of dissociation of the metal due to the stimulation pulse and due to ion imbalance. Likewise, the gastric wall varies in thickness (depending on location) from 4-5 mm to greater than 1 cm with the circular and longitudinal layers comprising approximately half that thickness. Additionally, the distal end contains the means for securely attaching the electrodes to the gastric wall. The fixation mechanism of the preferred embodiment is a pair of polymer tines that oppose each other and are located on either side of the electrode(s). FIG. 2A depicts the tine configuration at the distal end of the lead. An alternative fixation embodiment is to secure the lead to the gastric wall with a suture through the tissue and around an elastomer sleeve on the lead body. [0065]
  • The IGS is a small, compact pulse generator. Externally, it consists of a hermetic housing and a means for electrically and mechanically connecting the lead to the internal electronics. Internally, the IGS contains electronic circuitry and a power supply (battery and/or rf energy coupling circuitry). [0066]
  • In the preferred embodiment, the electronic circuitry consists of a microprocessor, electrical sensing (input) circuitry, electrical stimulation (output) circuitry, electrode switching circuitry, telemetry circuitry, and random access memory (reference FIG. 4). In an alternative embodiment, the IGS may have multiple sensing and/or stimulation circuits (channels) to provide more optimum sensing and stimulation to differing areas of the gastric system (reference FIG. 5). [0067]
  • The microprocessor is an integrated circuit that serves as an information processor that controls the IGS functions, performance, and analyses (if any). It receives inputs from the telemetry circuitry, the sensing circuitry, the RAM, and from internal functional checking. Depending upon the programming and the inputs, the microprocessor controls outputs to the telemetry circuitry, the stimulation circuitry, the RAM, and the electrode switching circuitry. The processor controls the basic timing and routing of the inputs and the output sequencing and parameters. [0068]
  • The sensing circuitry receives signals from the intrinsic gastric electrical activity via the selected sensing electrodes of the lead(s). The sensing input is utilized to classify the intrinsic gastric activity and as the trigger for the stimulation output. The sensing circuitry filters and amplifies the intrinsic signal and conveys it to the microprocessor. The sensing circuitry may employ a neural network approach to assist in the classification of the intrinsic gastric activity. The selection of the sensing electrodes, the timing of the sensing, and degree of amplification is controlled by the microprocessor and is programmable (via the telemetry circuitry). [0069]
  • The stimulation circuitry provides the electrical pulses employed for stimulation. The stimulation circuitry may invoke either a constant current approach or a constant voltage approach. In the preferred embodiment, the stimulation circuitry will provide pulses of programmable amplitude, frequency (pulses per second), and pulse width. An alternative embodiment entails the use of switching between individual capacitors in an array (switch cap technology) to provide adjacent or overlapping pulses of narrow width to achieve a continuous (or near continuous) pulse of a wider width. The stimulation circuitry is controlled by the microprocessor and is programmable. [0070]
  • The electrode switching circuitry establishes the function of each electrode and the polarity of the electrode. In the preferred embodiment, the electrode switching circuitry will enable a pair of electrodes to be used for sensing, and a pair or pairs of electrodes to be used for stimulation. FIGS. 6 and 7 depict possible sensing configurations (“pairs”) and possible stimulation vectors for a three and a four electrode system. The stimulation and sensing may utilize the same electrodes. During the stimulation period, the electrode switching circuitry can change the polarity of the stimulation electrodes to create multi-phasic pulses, alternating polarity between pulses or a series of pulses, and different stimulation vectors. Likewise, the switching circuitry can enable different pairs of sensing electrodes to sample gastric electrical activity at various sensing locations or along different vectors. Complex sensing patterns can be invoked to differentiate slow wave propagation direction and intervals. The switching circuitry may also include compensation (to offset internal leakage currents across the switches involved in sensing) and blanking to prevent stimulation pulses from saturating the sense amplifiers. The switching circuitry is controlled by the microprocessor and is programmable. Complex switching schemes can be stored in RAM and be activated as a program. The switching software would be designed to ensure that each configuration would have at least one bipolar pair to complete the electrical circuit. [0071]
  • The telemetry circuitry consists of an antenna and a transceiver. The circuitry may also include a telemetry buffer to accommodate large data transactions. The telemetry circuit transmits and receives pulses to and from the programmer. The circuitry may employ amplitude modulation, frequency modulation, or pulsed modulation at radio frequencies. In the preferred embodiment, the telemetry would have a range of several inches to allow for deep implantation of the IGS. The telemetry string would utilize an initiation protocol to establish two way communication, an identity packet to provide device/programmer identification, multiple information or programming packets to communicate the requisite data, error checking of the packets (cyclic redundancy checking or check sums) to ensure accuracy of the information, and a termination protocol to signal the end of the string. The incoming string would be processed by the microprocessor to set the parameters of the IGS. The outgoing string would basically acknowledge that the incoming string was accepted, confirm IGS settings or provide raw data/information for processing by the external programmer. [0072]
  • The RAM is used to store information and programs for the IGS. The RAM receives the sensed information about the intrinsic gastric activity from the microprocessor, analyzes that information to determine if the activity is normal according to a selected algorithm(s), and provides that analysis output to the microprocessor to initiate the therapy in accordance with the particular programming selected. Multiple programs may be stored in RAM to establish specific profiles of IGS activation, response, and performance. The RAM may also be used to store various parameters that indicate device performance, gastric activities, and therapies administered. [0073]
  • In use, the preferred embodiment of the invention operates as follows: [0074]
  • The electrodes of the lead(s) would be implanted (laparoscopically or through an open incision) in or on the gastric wall for communication with the circular layer of the gastric smooth muscle (reference FIG. 3). Since the lower portion of the stomach is primarily responsible for solids mixing and motility, the preferred location of the electrodes is the antrum, along the lesser curvature. The lesser curvature is preferable because it does not distend as much as the greater curvature and offers a more stable position. After the lead is secured, the IGS would be connected to the lead(s) and implanted in a subcutaneous or sub-fascial pocket in the patient's abdomen. [0075]
  • Normal gastric electrical activity progresses caudally from the pacemaker area of the fundus towards the pylorus at a rate of approximately 5 mm per second. The activity tends to speed up and organize as it progresses down the antrum. (FIG. 8 depicts the progression of a normal slow wave along the stomach from position A through position F.) The normal activity has pulse amplitudes, pulse widths, and frequency (intervals) that are discernible from abnormal activity. FIG. 9 depicts the discernible parameters that can be utilized to identify/classify the slow wave. [0076]
  • As the intrinsic activity crosses an implanted electrode, the depolarization of the cells will impart an electrical potential on that electrode (differentially compared to a second electrode in an area not undergoing depolarization). If the two electrodes have been programmed to serve as sensing electrodes, the electric potential is conveyed to the sensing circuitry. There it is filtered and amplified and presented to the information processor. The information processor (in conjunction with any RAM program/algorithm) identifies/classifies the activity as normal or abnormal. FIG. 10 depicts a string of gastric activity and the potential classification of the waves. If identified as normal, the information processor initiates stimulation as per the programmed parameters. If classified as abnormal, the microprocessor re-initiates sensing. Certain parameters of the intrinsic signal and stimulation are logged into RAM for history and for use in other algorithms. [0077]
  • An alternative embodiment of the invention analyzes the frequency components of the sensed signal for evidence of electrical response activity resulting from a contraction. If the signal contains frequencies that are associated with a contraction, a stronger type of stimulation is invoked to disrupt/disorganize or decouple the contraction. [0078]
  • The preferred embodiment may invoke one or multiple stimulation therapies that are dependent upon the activity sensed and the programmed therapeutic scheme. The stimulation may use electrical pulse trains of equally alternating polarity, electrical pulse trains of asymmetrically alternating polarity, and multiphasic pulses of equal or unequal phase widths. The stimulation may be delivered at a single or a plurality of sites. FIG. 11 depicts stimulation at multiple (two) sites. Additionally the stimulation vector can be switched (at any point) between any single pair of electrodes or plurality of electrodes providing that at least one bipolar pair is selected (reference FIGS. 6 and 7). The stimulation schemes are described as follows: [0079]
  • (a) Stimulation across a slow wave (FIG. 12). Stimulation across a slow wave occurs when the stimulation is applied between electrodes that lie on opposite sides of the slow wave. It is designed to depolarize cells prior to the wave induced depolarization. This will make the cells refractory to the wave and create an attenuation of the slow wave in the area of stimulation. Stimulation across the wave has a disadvantage in that some of the cells involved are already depolarized (as a result of the wave) and energy is wasted on those cells. [0080]
  • (b) Stimulation in advance (spatial offset) of propagation (FIG. 13). Stimulation in spatial advance of the propagating wave affords the advantage of only involving cells that are not part of the wave. The disadvantage is that the degree (length and direction/orientation) of the spatial offset must be considered to ensure that cell repolarization does not occur before the wave arrives. It may require relatively fixed configurations of electrodes placed in relation to the propagation path. [0081]
  • (c) Stimulation in advance (spatial and temporal offsets) of propagation (FIG. 14). Stimulation in advance of wave propagation with a temporal and a spatial offset involves sensing at one location and stimulation at a second location with a programmable delay to ensure that the cells do not repolarize before the wave arrives. It affords the advantage of a spatial offset and does not require precise electrode orientations to achieve the same ends. [0082]
  • (d) Anticipatory (temporal delay to anticipate the next wave) stimulation (FIG. 15). Anticipatory stimulation involves sensing between a pair of electrodes and delaying the stimulation until just prior to the next normal wave is anticipated. The stimulation may be applied to the sensing electrodes or any set of electrodes upstream from the sensing electrodes. The amount of delay is calculated from the history of normal intervals derived from the sensing identification and parameter storage. FIG. 16 depicts a running history used to calculate the expected interval timing until the next normal slow wave. The calculation would involve averaging a running history of normal intervals and subtracting a small time interval from that average. FIG. 17 depicts the anticipatory stimulation interval timing. [0083]
  • (e) Decoupling stimulation (FIG. 18). Decoupling stimulation involves sensing a peristaltic contraction at one location and strong stimulation at a second location to invoke a competing contraction that would propagate towards and away from the intrinsic contraction. Where the two contractions meet, they would tend to cancel each other. The advancing invoked contraction would not have the volume of chyme because it would precede the intrinsic movement and the efficiency of the gastric motility would be reduced. [0084]
  • (f) Ectopic stimulation. Ectopic stimulation involves overriding the intrinsic electrical activity by application of strong stimulation at an interval that is shorter than the intrinsic interval and at a location that does not afford a natural progression of the motility. The preferred location is on the gastric antrum close to the pylorus such that the majority of any propagation would be retrograde. [0085]
  • (g) Combined nerve and gastric stimulation. Combined nerve and gastric stimulation involves application of any of the previously listed therapy schemes with specific stimulation intended to suppress, block, or desensitize the enervation of the stomach. The stimulation could be a combination of pulse trains having neuro and muscular components or separate channels dedicated to the specific neural or muscular waveforms. [0086]
  • (h) Proportional stimulation. Proportional stimulation is a modulator of any or all of the previous stimulation schemes (except ectopic stimulation). In proportional stimulation, the disruptive, disorganizing, or decoupling stimulation is applied to a programmable percentage of the qualifying (normal) intrinsic activity. FIGS. 19 and 20 depict disorganization of 25% and 50% of the normal slow waves. (An alternative embodiment of FIG. 20 is disorganization of every other normal slow wave.) This type of stimulation allows the physician to modulate the intrinsic activity and still preserve some normal function. In addition, in times of increased abnormal gastric activity (such as when a patient is sick) proportional stimulation will be less frequent due to the decreased quantity of qualifying normal waves. [0087]
  • It should be recognized that the present invention may be used in many different electrophysiological stimulation embodiments, and all such variations or uses are contemplated by the present invention. While there has been described embodiments of the invention with respect to gastric stimulation and sensing, it will be clear that one skilled in the art may employ such in applications beyond the presently described preferred embodiments. Accordingly, it is intended that the scope of the invention, including such alternatives, modifications, and various shall be defined by the appended claims. [0088]

Claims (29)

What is claimed is:
1. A system for gastric stimulation of a patient comprising:
an implantable gastric stimulator, comprising an information processor, sensing circuitry, electrical stimulation circuitry, electrode switching circuitry, telemetry circuitry, a real time clock, and a power source;
a remote programmer operable with the telemetry circuitry of said implantable gastric stimulator for controlling the operation of the electrical stimulator and sensing circuitry with the information processor;
two or more electrodes for conveying electrical stimulation from the electrical stimulator circuit to the stomach wall of the patient; and
two or more electrodes for conveying sensed gastric electrical activity from the stomach wall to the sensing circuitry of the said implantable gastric stimulator.
2. A system as recited in claim 1, comprising one or a plurality of elongated lead body sheaths having proximal end connectors for coupling said stimulation and sensing electrodes with said implantable gastric stimulator, the leads of said stimulation and sensing electrodes extending through the elongated lead body sheaths to their distal end, the distal end of the elongated lead body sheaths for electrical communication with the stomach wall of the patient and for positioning said stimulation and sensing electrodes on or in the stomach wall.
3. A system as recited in claim 1, wherein said plurality of the stimulation and sensing electrodes are positionable at different locations of the stomach wall.
4. A system as recited in claim 1, wherein the function of the electrodes is controlled by programmable electrode switching circuitry.
5. A system as recited in claim 1, wherein the telemetry circuitry of said implantable gastric stimulator comprises a radio frequency telemetry transceiver provided for communication with said remote programmer.
6. A system as recited in claim 1, wherein said information processor comprises a programmable microprocessor or microcontroller.
7. A system as recited in claim 1, wherein the system may temporarily revert to a power conserve condition at programmable times of the day.
8. A system as recited in claim 1, wherein said sensing electrodes communicate gastric electrical signals to the sensing circuitry of said implantable gastric stimulator for processing with the information processor for identifying interval, amplitude, and duration of the intrinsic electrical activity.
9. A system as recited in claim 8, wherein said sensing electrodes communicate gastric electrical signals to the sensing circuitry of said implantable gastric stimulator for processing with the information processor for identifying the frequency spectrum of the intrinsic electrical activity.
10. A system as recited in claim 9, wherein the information processor analyzes the electrical activity and classifies it as slow wave or peristaltic wave.
11. A system as recited in claim 10, wherein the information processor analyzes the intrinsic electrical activity and classifies the activity as normal or abnormal.
12. A system as recited in claim 11, wherein the system may temporarily revert to a power conserve condition in the absence of a programmable threshold of normal electrical activity.
13. A system as recited in claim 12, wherein the stimulator delivery of electrical stimulation is triggered by electrical activity classified as normal.
14. A system as recited in claim 13, wherein the stimulator may be programmed to deliver electrical stimulation on all or a percentage of normal events.
15. A system as recited in claim 14, wherein the electrical stimulation may be delivered across the intrinsic electrical activity.
16. A system as recited in claim 14, wherein the electrical stimulation may be delivered with a spatial offset to the intrinsic electrical activity.
17. A system as recited in claim 16, wherein the electrical stimulation may be delivered with a temporal offset to the sensed intrinsic electrical activity.
18. A system as recited in claim 17, wherein the electrical stimulation may be delivered in anticipation of the next normal electrical activity.
19. A system as recited in claim 18, wherein the temporal offset is programmable.
20. A system as recited in claim 19, wherein the temporal delivery of the electrical stimulation is adaptable based upon an algorithm considering a running history of recent predecessor electrical activity events.
21. A system as recited in claim 20, wherein the polarity of the stimulation electrodes is programmable allowing stimulation between a single pair or a plurality of electrodes.
22. A system as recited in claim 21, wherein the stimulator may be programmed to switch the polarity of one or a plurality of the various stimulation electrodes to accommodate multiphase stimulation.
23. A system as recited in claim 22, wherein the electrical stimulation comprises one or a plurality of biphasic pulses programmable within the following parameters, comprising:
pulse amplitude between 0.0 to 15 V or 0.0 to 15 mA;
pulse width between 20 msec to 500 msec;
pulses per event between 1 and 5; and
first phase width between 25 to 100 percent of pulse width.
24. A method for claim 23, wherein the pulse width is accommodated by switching between two or more capacitors in an array.
25. A system as recited in claim 22, wherein the electrical stimulation comprises an alternating polarity pulse train programmable within the following parameters, comprising:
pulse amplitude between 0.0 to 15 V or 0.0 to 15 mA; pulse width between 100 μsec and 750 μsec;
pulses per second (frequency) between 10 to 120 Hz; and
duration of pulse train between 0.5 and 30 seconds.
26. A system as recited in claim 25, wherein parameters comprising quantities, interval frequency, duration, amplitude, or the like for the sensed events and quantities of paced events are stored for subsequent recall.
27. A system as recited in claim 26, wherein the sensed intrinsic waveforms can be telemetered to the external programmer to assist in establishing the appropriate stimulation parameters.
28. A system as recited in claim 1, wherein the stimulator may incorporate one or a plurality of independently programmable stimulation or sensing channels.
29. A system as recited in claim 28, wherein at least one stimulation channel may be programmable to parameters associated with nerve stimulation.
US09/963,149 2000-09-26 2001-09-25 Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity Abandoned US20020072780A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/963,149 US20020072780A1 (en) 2000-09-26 2001-09-25 Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US10/782,087 US7941221B2 (en) 2000-09-26 2004-02-19 Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23566000P 2000-09-26 2000-09-26
US09/963,149 US20020072780A1 (en) 2000-09-26 2001-09-25 Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/782,087 Continuation US7941221B2 (en) 2000-09-26 2004-02-19 Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity

Publications (1)

Publication Number Publication Date
US20020072780A1 true US20020072780A1 (en) 2002-06-13

Family

ID=22886416

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/963,149 Abandoned US20020072780A1 (en) 2000-09-26 2001-09-25 Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US10/782,087 Active 2024-09-19 US7941221B2 (en) 2000-09-26 2004-02-19 Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/782,087 Active 2024-09-19 US7941221B2 (en) 2000-09-26 2004-02-19 Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity

Country Status (8)

Country Link
US (2) US20020072780A1 (en)
EP (1) EP1322380A4 (en)
JP (1) JP2004509714A (en)
CN (1) CN1476339A (en)
AU (1) AU2001293039A1 (en)
CA (1) CA2421846A1 (en)
NO (1) NO20031348L (en)
WO (1) WO2002026317A1 (en)

Cited By (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144708A1 (en) * 2002-01-29 2003-07-31 Starkebaum Warren L. Methods and apparatus for retarding stomach emptying for treatment of eating disorders
US20030167025A1 (en) * 2001-05-01 2003-09-04 Imran Mir A. Gastric treatment/diagnosis device and attachment device and method
US20030181959A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Wireless electric modulation of sympathetic nervous system
US20030181958A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Electric modulation of sympathetic nervous system
WO2003099376A1 (en) * 2002-05-23 2003-12-04 Transneuronix, Inc. Improved process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease
US20040162595A1 (en) * 2000-09-26 2004-08-19 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US20040172086A1 (en) * 2003-02-03 2004-09-02 Beta Medical, Inc. Nerve conduction block treatment
US20040230255A1 (en) * 2002-03-22 2004-11-18 Dobak John D. Splanchnic nerve stimulation for treatment of obesity
US20040267330A1 (en) * 2003-04-25 2004-12-30 Lee Michael T. Generation of theraphy programs and program groups
US20050038484A1 (en) * 2003-02-03 2005-02-17 Enteromedics, Inc. Controlled vagal blockage therapy
US20050065575A1 (en) * 2002-09-13 2005-03-24 Dobak John D. Dynamic nerve stimulation for treatment of disorders
US20050065571A1 (en) * 2001-05-01 2005-03-24 Imran Mir A. Responsive gastric stimulator
US20050090873A1 (en) * 2003-10-22 2005-04-28 Imran Mir A. Gastrointestinal stimulation device
US20050131485A1 (en) * 2003-02-03 2005-06-16 Enteromedics, Inc. High frequency vagal blockage therapy
US20050128187A1 (en) * 2003-12-12 2005-06-16 Yu-Yu Chen Computer cursor pointing device with electric stimulator
US20050137643A1 (en) * 2003-11-28 2005-06-23 Mintchev Martin P. Gastrointestinal motility control
US20050143784A1 (en) * 2001-05-01 2005-06-30 Imran Mir A. Gastrointestinal anchor with optimal surface area
US20050149141A1 (en) * 2004-01-07 2005-07-07 Starkebaum Warren L. Gastric stimulation for altered perception to treat obesity
US20050187597A1 (en) * 2004-02-25 2005-08-25 Vanderschuit Carl R. Therapeutic devices and methods for applying therapy
US20050222638A1 (en) * 2004-03-30 2005-10-06 Steve Foley Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders
US20050222637A1 (en) * 2004-03-30 2005-10-06 Transneuronix, Inc. Tachygastrial electrical stimulation
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US20060036293A1 (en) * 2004-08-16 2006-02-16 Whitehurst Todd K Methods for treating gastrointestinal disorders
US20060074457A1 (en) * 2001-05-01 2006-04-06 Imran Mir A Pseudounipolar lead for stimulating a digestive organ
US20060074458A1 (en) * 2001-05-01 2006-04-06 Imran Mir A Digestive organ retention device
US20060074459A1 (en) * 2000-12-11 2006-04-06 Melina Flesler Acute and chronic electrical signal therapy for obesity
US20060070334A1 (en) * 2004-09-27 2006-04-06 Blue Hen, Llc Sidewall plank for constructing a trailer and associated trailer sidewall construction
US20060089699A1 (en) * 2001-05-01 2006-04-27 Imran Mir A Abdominally implanted stimulator and method
US20060190053A1 (en) * 2002-03-22 2006-08-24 Dobak John D Iii Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US20060235448A1 (en) * 2005-04-13 2006-10-19 Roslin Mitchell S Artificial gastric valve
US20070043411A1 (en) * 2005-08-17 2007-02-22 Enteromedics Inc. Neural electrode
US20070043400A1 (en) * 2005-08-17 2007-02-22 Donders Adrianus P Neural electrode treatment
US20070049986A1 (en) * 2005-09-01 2007-03-01 Imran Mir A Randomized stimulation of a gastrointestinal organ
US20070078494A1 (en) * 2005-09-23 2007-04-05 Mintchev Martin P Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity
US20070135857A1 (en) * 2003-02-03 2007-06-14 Enteromedics, Inc. GI inflammatory disease treatment
US20070203521A1 (en) * 2002-03-22 2007-08-30 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes
US20070255154A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Activity level feedback for managing obesity
US20070255334A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Energy balance therapy for obesity management
US20070282390A1 (en) * 2006-06-06 2007-12-06 Shuros Allan C Amelioration of chronic pain by endolymphatic stimulation
US20070282387A1 (en) * 2006-05-17 2007-12-06 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
US20070282386A1 (en) * 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for gastrointestinal stimulation via the lymphatic system
US20080009719A1 (en) * 2006-06-06 2008-01-10 Shuros Allan C Method and apparatus for introducing endolymphatic instrumentation
US20080033511A1 (en) * 2002-03-22 2008-02-07 Leptos Biomedical, Inc. Dynamic nerve stimulation employing frequency modulation
US20080065169A1 (en) * 2001-05-01 2008-03-13 Intrapace, Inc. Endoscopic Instrument for Engaging a Device
US20080097412A1 (en) * 2006-09-01 2008-04-24 Shuros Allan C Method and apparatus for endolymphatic drug delivery
US7371215B2 (en) 2001-05-01 2008-05-13 Intrapace, Inc. Endoscopic instrument for engaging a device
US20080183238A1 (en) * 2002-07-26 2008-07-31 Medtronic, Inc. Process for electrostimulation treatment of morbid obesity
US20080195171A1 (en) * 2007-02-13 2008-08-14 Sharma Virender K Method and Apparatus for Electrical Stimulation of the Pancreatico-Biliary System
US20080262411A1 (en) * 2006-06-02 2008-10-23 Dobak John D Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US20080281365A1 (en) * 2007-05-09 2008-11-13 Tweden Katherine S Neural signal duty cycle
US20080294228A1 (en) * 2007-05-23 2008-11-27 Cardiac Pacemakers Method and device for controlled stimulation of lymphatic flow
US20090018606A1 (en) * 2005-10-12 2009-01-15 Intrapace, Inc. Methods and Devices for Stimulation of an Organ with the Use of a Transectionally Placed Guide Wire
US20090030474A1 (en) * 2007-06-29 2009-01-29 Intrapace, Inc. Sensor Driven Gastric Stimulation for Patient Management
US20090030475A1 (en) * 2007-07-25 2009-01-29 Intrapace, Inc. Gastric Stimulation Systems and Methods Utilizing a Transgastric Probe
CN100469401C (en) * 2005-10-28 2009-03-18 清华大学 Implant nervous electric pulse stimulus system
US7509175B2 (en) 2006-08-03 2009-03-24 Intrapace, Inc. Method and devices for stimulation of an organ with the use of a transectionally placed guide wire
US20090088819A1 (en) * 2007-10-01 2009-04-02 Medtronic, Inc. Gastric electrical stimulation with multi-site stimulation anti-desensitization feature
US20090118777A1 (en) * 2007-08-09 2009-05-07 Kobi Iki Efferent and afferent splanchnic nerve stimulation
US20090157138A1 (en) * 2006-04-18 2009-06-18 Electrocore, Inc. Methods And Apparatus For Treating Ileus Condition Using Electrical Signals
US20090234417A1 (en) * 2005-11-10 2009-09-17 Electrocore, Inc. Methods And Apparatus For The Treatment Of Metabolic Disorders
US20090259279A1 (en) * 2002-03-22 2009-10-15 Dobak Iii John D Splanchnic nerve stimulation for treatment of obesity
US7623924B2 (en) 2004-08-31 2009-11-24 Leptos Biomedical, Inc. Devices and methods for gynecologic hormone modulation in mammals
US20090312785A1 (en) * 2008-06-11 2009-12-17 Allergan, Inc. Implantable Pump System
US20100057178A1 (en) * 2006-04-18 2010-03-04 Electrocore, Inc. Methods and apparatus for spinal cord stimulation using expandable electrode
US20100076508A1 (en) * 2008-09-25 2010-03-25 Boston Scientific Neuromodulation Corporation Electrical stimulation leads having rf compatibility and methods of use and manufacture
US20100160745A1 (en) * 2008-12-12 2010-06-24 Intrapace, Inc. Detection of Food or Drink Consumption In Order to Control Therapy or Provide Diagnostics
US7756582B2 (en) 2001-05-01 2010-07-13 Intrapace, Inc. Gastric stimulation anchor and method
US20100228313A1 (en) * 2009-03-03 2010-09-09 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
US20100234917A1 (en) * 2001-05-01 2010-09-16 Intrapace, Inc. Digestive Organ Retention Device
US20100268297A1 (en) * 2009-02-24 2010-10-21 Hans Neisz Duodenal Stimulation To Induce Satiety
US7837719B2 (en) 2002-05-09 2010-11-23 Daemen College Electrical stimulation unit and waterbath system
US20100324611A1 (en) * 2008-12-10 2010-12-23 Waverx, Inc. Devices, systems and methods for preventing and treating sensation loss
US20110034760A1 (en) * 2009-04-03 2011-02-10 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments
US20110071589A1 (en) * 2009-09-21 2011-03-24 Medtronic, Inc. Waveforms for electrical stimulation therapy
US20110190844A1 (en) * 2005-07-29 2011-08-04 Medtronic, Inc. Transmembrane sensing device for sensing bladder condition
US20110201875A1 (en) * 2010-02-12 2011-08-18 Allergan, Inc. Remotely adjustable gastric banding system
US20110201874A1 (en) * 2010-02-12 2011-08-18 Allergan, Inc. Remotely adjustable gastric banding system
US20110257760A1 (en) * 2010-04-15 2011-10-20 Waldrep Donald J Gastric implant and method for use of same
US8236023B2 (en) 2004-03-18 2012-08-07 Allergan, Inc. Apparatus and method for volume adjustment of intragastric balloons
US8295926B2 (en) 2006-06-02 2012-10-23 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US8308630B2 (en) 2006-01-04 2012-11-13 Allergan, Inc. Hydraulic gastric band with collapsible reservoir
US8317677B2 (en) 2008-10-06 2012-11-27 Allergan, Inc. Mechanical gastric band with cushions
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
US8340772B2 (en) 2009-05-08 2012-12-25 Advanced Neuromodulation Systems, Inc. Brown adipose tissue utilization through neuromodulation
US8369943B2 (en) 2006-06-06 2013-02-05 Cardiac Pacemakers, Inc. Method and apparatus for neural stimulation via the lymphatic system
US8377081B2 (en) 2004-03-08 2013-02-19 Allergan, Inc. Closure system for tubular organs
US8382780B2 (en) 2002-08-28 2013-02-26 Allergan, Inc. Fatigue-resistant gastric banding device
US8517915B2 (en) 2010-06-10 2013-08-27 Allergan, Inc. Remotely adjustable gastric banding system
US8630715B2 (en) 2006-04-12 2014-01-14 Medtronic, Inc. Rule-based stimulation program search
US20140072929A1 (en) * 2003-06-19 2014-03-13 Osstell Ab Method and arrangement relating to testing objects
US8698373B2 (en) 2010-08-18 2014-04-15 Apollo Endosurgery, Inc. Pare piezo power with energy recovery
US8758221B2 (en) 2010-02-24 2014-06-24 Apollo Endosurgery, Inc. Source reservoir with potential energy for remotely adjustable gastric banding system
US8764624B2 (en) 2010-02-25 2014-07-01 Apollo Endosurgery, Inc. Inductively powered remotely adjustable gastric banding system
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US8840541B2 (en) 2010-02-25 2014-09-23 Apollo Endosurgery, Inc. Pressure sensing gastric banding system
US8845513B2 (en) 2002-08-13 2014-09-30 Apollo Endosurgery, Inc. Remotely adjustable gastric banding device
US8876694B2 (en) 2011-12-07 2014-11-04 Apollo Endosurgery, Inc. Tube connector with a guiding tip
US8900117B2 (en) 2004-01-23 2014-12-02 Apollo Endosurgery, Inc. Releasably-securable one-piece adjustable gastric band
US8900118B2 (en) 2008-10-22 2014-12-02 Apollo Endosurgery, Inc. Dome and screw valves for remotely adjustable gastric banding systems
US8905915B2 (en) 2006-01-04 2014-12-09 Apollo Endosurgery, Inc. Self-regulating gastric band with pressure data processing
US8934976B2 (en) 2004-09-23 2015-01-13 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors
US8961393B2 (en) 2010-11-15 2015-02-24 Apollo Endosurgery, Inc. Gastric band devices and drive systems
US8961394B2 (en) 2011-12-20 2015-02-24 Apollo Endosurgery, Inc. Self-sealing fluid joint for use with a gastric band
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9028394B2 (en) 2010-04-29 2015-05-12 Apollo Endosurgery, Inc. Self-adjusting mechanical gastric band
US9044298B2 (en) 2010-04-29 2015-06-02 Apollo Endosurgery, Inc. Self-adjusting gastric band
US9050165B2 (en) 2010-09-07 2015-06-09 Apollo Endosurgery, Inc. Remotely adjustable gastric banding system
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9192501B2 (en) 2010-04-30 2015-11-24 Apollo Endosurgery, Inc. Remotely powered remotely adjustable gastric band system
US9211207B2 (en) 2010-08-18 2015-12-15 Apollo Endosurgery, Inc. Power regulated implant
US9226840B2 (en) 2010-06-03 2016-01-05 Apollo Endosurgery, Inc. Magnetically coupled implantable pump system and method
US9295573B2 (en) 2010-04-29 2016-03-29 Apollo Endosurgery, Inc. Self-adjusting gastric band having various compliant components and/or a satiety booster
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9668690B1 (en) 2001-05-01 2017-06-06 Intrapace, Inc. Submucosal gastric implant device and method
US9950171B2 (en) 2014-10-31 2018-04-24 Medtronic, Inc. Paired stimulation pulses based on sensed compound action potential
US10376694B2 (en) 2008-10-09 2019-08-13 Virender K. Sharma Method and apparatus for stimulating the vascular system
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4175662B2 (en) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ.ヴイ. Electric muscle control device
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US8825152B2 (en) 1996-01-08 2014-09-02 Impulse Dynamics, N.V. Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue
US9713723B2 (en) * 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US8700161B2 (en) 1999-03-05 2014-04-15 Metacure Limited Blood glucose level control
WO2001091854A1 (en) * 2000-05-31 2001-12-06 Impulse Dynamics Nv Electropancreatography
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
JP4246492B2 (en) * 2001-01-05 2009-04-02 メタキュアー ナームロゼ フェンノートシャップ Regulation of eating habits
AU2002255245A1 (en) 2001-04-18 2002-10-28 Impulse Dynamics Nv Analysis of eating habits
EP1455892A4 (en) * 2001-11-29 2008-03-26 Metacure N V Sensing of pancreatic electrical activity
US6937891B2 (en) 2002-04-26 2005-08-30 Medtronic, Inc. Independent therapy programs in an implantable medical device
CN1787850B (en) 2003-03-10 2015-12-16 脉冲动力公司 For transmitting the signal of telecommunication to revise the apparatus and method of gene expression in heart tissue
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
US7502649B2 (en) * 2003-06-20 2009-03-10 Metacure Ltd. Gastrointestinal methods and apparatus for use in treating disorders
US20070060971A1 (en) * 2003-07-21 2007-03-15 Ofer Glasberg Hepatic device for treatment or glucose detection
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US7931693B2 (en) 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US8548583B2 (en) 2004-03-10 2013-10-01 Impulse Dynamics Nv Protein activity modification
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
EP1747043A4 (en) 2004-05-04 2008-04-23 Univ Rochester Implantable bio-electro-physiologic interface matrix
WO2006018851A2 (en) 2004-08-18 2006-02-23 Metacure Ltd. Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
WO2007080595A2 (en) 2006-01-12 2007-07-19 Metacure N.V. Electrode assemblies, tools, and methods for gastric wall implantation
US20060247717A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Electrical stimulation of the gastrointestinal tract to regulate motility
EP1890763A4 (en) 2005-06-02 2017-05-03 Metacure Limited Gi lead implantation
US8442841B2 (en) 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
EP1852143B1 (en) * 2006-05-03 2013-04-10 Medtronic, Inc. Electrode for implantation in a living organ
US9020597B2 (en) 2008-11-12 2015-04-28 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
WO2007139920A2 (en) * 2006-05-26 2007-12-06 Endosphere, Inc. Improvements in methods and devices to curb appetite and/or reduce food intake
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US9345879B2 (en) 2006-10-09 2016-05-24 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US9724510B2 (en) 2006-10-09 2017-08-08 Endostim, Inc. System and methods for electrical stimulation of biological systems
US20150224310A1 (en) 2006-10-09 2015-08-13 Endostim, Inc. Device and Implantation System for Electrical Stimulation of Biological Systems
US11577077B2 (en) 2006-10-09 2023-02-14 Endostim, Inc. Systems and methods for electrical stimulation of biological systems
US8417342B1 (en) * 2007-07-03 2013-04-09 University Of Mississippi Medical Center Gastrointestinal electrical stimulation device and method for treating gastrointestinal disorders
US20110137227A1 (en) 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
WO2011092710A2 (en) 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
US11717681B2 (en) 2010-03-05 2023-08-08 Endostim, Inc. Systems and methods for treating gastroesophageal reflux disease
US8447404B2 (en) 2010-03-05 2013-05-21 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
FR2958857B1 (en) * 2010-04-16 2012-06-22 Inst Nat Rech Inf Automat DEVICE AND SYSTEM FOR MONITORING THE HUMAN BODY
CN102049096B (en) * 2010-12-22 2013-07-10 重庆邮电大学 Independent feedback type stomach pace-making device
EP2696792B8 (en) 2011-04-14 2018-05-23 Endostim, Inc. Systems for treating gastroesophageal reflux disease
AU2012250686B2 (en) * 2011-05-03 2016-11-03 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US9925367B2 (en) 2011-09-02 2018-03-27 Endostim, Inc. Laparoscopic lead implantation method
CN102500057B (en) * 2011-09-28 2014-02-26 上海交通大学 Multifunctional implanted gastrointestinal electrical stimulation system
CN104736197A (en) 2012-08-23 2015-06-24 恩多斯提姆公司 Device and implantation system for electrical stimulation of biological systems
US9498619B2 (en) 2013-02-26 2016-11-22 Endostim, Inc. Implantable electrical stimulation leads
EP3041564A4 (en) 2013-09-03 2017-03-29 Endostim, Inc. Methods and systems of electrode polarity switching in electrical stimulation therapy
US9919152B2 (en) 2014-11-05 2018-03-20 Enterastim, Inc. Conditional gastrointestinal stimulation for improved motility
US9682234B2 (en) 2014-11-17 2017-06-20 Endostim, Inc. Implantable electro-medical device programmable for improved operational life
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
CN115227969A (en) 2015-02-24 2022-10-25 伊莱拉股份有限公司 Method for achieving appetite regulation or improving dietary compliance using electrode patches
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
CA2980482C (en) * 2015-06-01 2023-09-26 Saluda Medical Pty Ltd Motor fibre neuromodulation
CN105521561B (en) * 2015-12-30 2018-06-12 宁波贝思转化医学研究中心有限公司 A kind of closed circuit small intestine electrical stimulation device
US20180056063A1 (en) 2016-08-26 2018-03-01 New York Institute Of Technology Closed loop system for modulating gastric activity and use thereof
WO2018094207A1 (en) 2016-11-17 2018-05-24 Endostim, Inc. Modular stimulation system for the treatment of gastrointestinal disorders
CN108210017A (en) * 2018-03-05 2018-06-29 江秀秀 A kind of surgical clamp and the method for judging clamped organization type
US11511105B2 (en) * 2018-05-18 2022-11-29 Musc Foundation For Research Development Noninvasive cranial nerve therapy
CN110064130A (en) * 2019-04-17 2019-07-30 上海黎欧生物科技有限公司 A kind of gall-bladder pacemaker
US20210290272A1 (en) * 2020-01-13 2021-09-23 Xiangyang Ma Customized posterior atlantoaxial reduction fixatorwith screws and rods
US20230098646A1 (en) * 2021-09-30 2023-03-30 Massachusetts Institute Of Technology Neuromodulation devices and related methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US6327503B1 (en) * 1997-04-30 2001-12-04 Medtronic, Inc Method and apparatus for sensing and stimulating gastrointestinal tract on-demand

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2865376A (en) 1956-03-27 1958-12-23 American Cyanamid Co Gold plating surgical needles
US3760812A (en) 1971-03-19 1973-09-25 Univ Minnesota Implantable spiral wound stimulation electrodes
US4444207A (en) 1981-10-19 1984-04-24 Cordis Corporation Method of anchoring a temporary cardiac pacing lead
US4475560A (en) 1982-04-29 1984-10-09 Cordis Corporation Temporary pacing lead assembly
US4524771A (en) 1982-10-28 1985-06-25 Ethicon Inc. Multiple curved surgical needle
KR950000058B1 (en) 1986-06-12 1995-01-09 가부시끼가이샤 뮤텍크 Suturing needle with suture and method of producing the same
US5059207A (en) 1990-08-27 1991-10-22 Shah Mrugesh K Shaped needles for specialized surgical procedures
US5100431A (en) 1990-09-27 1992-03-31 Allergan, Inc. Single stitch suture needle and method
US5263480A (en) * 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5217471A (en) 1991-05-30 1993-06-08 Burkhart Stephen S Endoscopic suture knotting instrument
US5242458A (en) 1991-10-15 1993-09-07 Ethicon, Inc. Suture needle holder for endoscopic use
IT1260485B (en) * 1992-05-29 1996-04-09 PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT
US5292344A (en) * 1992-07-10 1994-03-08 Douglas Donald D Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port
US5388441A (en) 1992-12-29 1995-02-14 United States Surgical Corporation Needle curver with automatic feed
US5423876A (en) 1993-12-09 1995-06-13 Medtronic, Inc. Intramuscular lead having improved insertion
DE4402058C1 (en) 1994-01-25 1995-04-13 Andreas Dr Med Asch Implantable temporary electrode cable
US5489294A (en) 1994-02-01 1996-02-06 Medtronic, Inc. Steroid eluting stitch-in chronic cardiac lead
US5433728A (en) 1994-03-02 1995-07-18 Kim; Il G. Surgical needle
US5484404A (en) 1994-05-06 1996-01-16 Alfred E. Mann Foundation For Scientific Research Replaceable catheter system for physiological sensors, tissue stimulating electrodes and/or implantable fluid delivery systems
US5540730A (en) 1995-06-06 1996-07-30 Cyberonics, Inc. Treatment of motility disorders by nerve stimulation
US5716392A (en) 1996-01-05 1998-02-10 Medtronic, Inc. Minimally invasive medical electrical lead
US5861104A (en) * 1996-03-28 1999-01-19 Advanced Micro Devices Trench isolation with rounded top and bottom corners and edges
US6453199B1 (en) 1996-04-01 2002-09-17 Valery Ivanovich Kobozev Electrical gastro-intestinal tract stimulator
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
CA2264831C (en) 1996-09-05 2003-08-12 The Governors Of The University Of Alberta Gastro-intestinal electrical pacemaker
US6026326A (en) * 1997-01-13 2000-02-15 Medtronic, Inc. Apparatus and method for treating chronic constipation
US5836994A (en) * 1997-04-30 1998-11-17 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US6216039B1 (en) * 1997-05-02 2001-04-10 Medtronic Inc. Method and apparatus for treating irregular gastric rhythms
IT1292016B1 (en) 1997-05-28 1999-01-25 Valerio Cigaina IMPLANT DEVICE PARTICULARLY FOR ELECTROSTIMULATION AND / OR ELECTRO-REGISTRATION OF ENDOABDOMINAL VISCERS
US6321124B1 (en) 1997-05-28 2001-11-20 Transneuronix, Inc. Implant device for electrostimulation and/or monitoring of endo-abdominal cavity tissue
IL133902A0 (en) 1997-07-16 2001-04-30 Impulse Dynamics Ltd Smooth muscle controller
US20030054463A1 (en) 1997-10-24 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6104955A (en) 1997-12-15 2000-08-15 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US6091992A (en) 1997-12-15 2000-07-18 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
IT1301986B1 (en) 1998-07-31 2000-07-20 Valerio Cigaina LAPAROSCOPIC FORCEPS FOR SUTURE.
US7599736B2 (en) 2001-07-23 2009-10-06 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
US6097984A (en) * 1998-11-25 2000-08-01 Medtronic, Inc. System and method of stimulation for treating gastro-esophageal reflux disease
US6098672A (en) 1999-01-14 2000-08-08 Kiholm Industries Llc Method and apparatus for a product recovery system
US6895278B1 (en) * 1999-04-14 2005-05-17 Transneuronix, Inc. Gastric stimulator apparatus and method for use
US6606523B1 (en) 1999-04-14 2003-08-12 Transneuronix Inc. Gastric stimulator apparatus and method for installing
US6542776B1 (en) 1999-04-14 2003-04-01 Transneuronix Inc. Gastric stimulator apparatus and method for installing
US6510332B1 (en) 1999-08-30 2003-01-21 Transneuronix, Inc. Electrode leads for use in laparoscopic surgery
US6853862B1 (en) 1999-12-03 2005-02-08 Medtronic, Inc. Gastroelectric stimulation for influencing pancreatic secretions
US6600953B2 (en) 2000-12-11 2003-07-29 Impulse Dynamics N.V. Acute and chronic electrical signal therapy for obesity
CN1476339A (en) 2000-09-26 2004-02-18 特兰施钮罗尼克斯股份有限公司 Method and apparatus for treating obesity by electrical stimulation of gastrointestinal tract using sensed activity
US6591137B1 (en) 2000-11-09 2003-07-08 Neuropace, Inc. Implantable neuromuscular stimulator for the treatment of gastrointestinal disorders
US6615084B1 (en) 2000-11-15 2003-09-02 Transneuronix, Inc. Process for electrostimulation treatment of morbid obesity
US7020531B1 (en) 2001-05-01 2006-03-28 Intrapace, Inc. Gastric device and suction assisted method for implanting a device on a stomach wall
US6678561B2 (en) 2001-05-23 2004-01-13 Surgical Development Ag Heartburn and reflux disease treatment apparatus
US7160258B2 (en) 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
US6735477B2 (en) 2001-07-09 2004-05-11 Robert A. Levine Internal monitoring system with detection of food intake
US20040193229A1 (en) 2002-05-17 2004-09-30 Medtronic, Inc. Gastric electrical stimulation for treatment of gastro-esophageal reflux disease
CN1713933A (en) 2002-07-26 2005-12-28 特兰施钮罗尼克斯股份有限公司 Process for electrostimulation treatment of morbid obesity
US7620454B2 (en) 2003-05-19 2009-11-17 Medtronic, Inc. Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof
US7742818B2 (en) 2003-05-19 2010-06-22 Medtronic, Inc. Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof
CA2588727C (en) 2003-11-28 2014-01-14 University Technologies International Inc. Gastrointestinal motility control
US7177693B2 (en) 2004-01-07 2007-02-13 Medtronic, Inc. Gastric stimulation for altered perception to treat obesity
US20050209653A1 (en) 2004-03-16 2005-09-22 Medtronic, Inc. Intra-luminal device for gastrointestinal electrical stimulation
US20050222638A1 (en) 2004-03-30 2005-10-06 Steve Foley Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US6327503B1 (en) * 1997-04-30 2001-12-04 Medtronic, Inc Method and apparatus for sensing and stimulating gastrointestinal tract on-demand

Cited By (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162595A1 (en) * 2000-09-26 2004-08-19 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US7941221B2 (en) 2000-09-26 2011-05-10 Medtronic, Inc. Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US20060206160A1 (en) * 2000-11-15 2006-09-14 Transneuronix, Inc. Process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease
US7512442B2 (en) * 2000-12-11 2009-03-31 Metacure N.V. Acute and chronic electrical signal therapy for obesity
US20060074459A1 (en) * 2000-12-11 2006-04-06 Melina Flesler Acute and chronic electrical signal therapy for obesity
US7979127B2 (en) 2001-05-01 2011-07-12 Intrapace, Inc. Digestive organ retention device
US20050236277A9 (en) * 2001-05-01 2005-10-27 Imran Mir A Aendoscopic instrument system@
US20040088023A1 (en) * 2001-05-01 2004-05-06 Imran Mir A. Gastric treatment and diagnosis device and method
US7747322B2 (en) 2001-05-01 2010-06-29 Intrapace, Inc. Digestive organ retention device
US20100234917A1 (en) * 2001-05-01 2010-09-16 Intrapace, Inc. Digestive Organ Retention Device
US7702394B2 (en) 2001-05-01 2010-04-20 Intrapace, Inc. Responsive gastric stimulator
US7689284B2 (en) 2001-05-01 2010-03-30 Intrapace, Inc. Pseudounipolar lead for stimulating a digestive organ
US7643887B2 (en) 2001-05-01 2010-01-05 Intrapace, Inc. Abdominally implanted stimulator and method
US20100305656A1 (en) * 2001-05-01 2010-12-02 Intrapace, Inc. Gastric Simulation Anchor and Method
US20050065571A1 (en) * 2001-05-01 2005-03-24 Imran Mir A. Responsive gastric stimulator
US20090299434A1 (en) * 2001-05-01 2009-12-03 Intrapace, Inc. Endoscopic System For Attaching a Device to a Stomach
US7590452B2 (en) 2001-05-01 2009-09-15 Intrapace, Inc. Endoscopic system for attaching a device to a stomach
US20030167025A1 (en) * 2001-05-01 2003-09-04 Imran Mir A. Gastric treatment/diagnosis device and attachment device and method
US20090149910A1 (en) * 2001-05-01 2009-06-11 Inrapace, Inc. Gastric Treatment/Diagnosis Device and Attachment Device and Method
US20050143784A1 (en) * 2001-05-01 2005-06-30 Imran Mir A. Gastrointestinal anchor with optimal surface area
US7756582B2 (en) 2001-05-01 2010-07-13 Intrapace, Inc. Gastric stimulation anchor and method
US20090099415A1 (en) * 2001-05-01 2009-04-16 Intrapace, Inc. Endoscopic Instrument System for Implanting a Device in the Stomach
US20030164304A1 (en) * 2001-05-01 2003-09-04 Imran Mir A. Aendoscopic instrument system@
US9668690B1 (en) 2001-05-01 2017-06-06 Intrapace, Inc. Submucosal gastric implant device and method
US20080065169A1 (en) * 2001-05-01 2008-03-13 Intrapace, Inc. Endoscopic Instrument for Engaging a Device
US8019422B2 (en) 2001-05-01 2011-09-13 Intrapace, Inc. Gastric device and endoscopic delivery system
US9517152B2 (en) 2001-05-01 2016-12-13 Intrapace, Inc. Responsive gastric stimulator
US7016735B2 (en) 2001-05-01 2006-03-21 Intrapace, Inc. Gastric anchor and method
US20060069414A1 (en) * 2001-05-01 2006-03-30 Imran Mir A Endoscopic instrument system for implanting a device in the stomach
US20060074457A1 (en) * 2001-05-01 2006-04-06 Imran Mir A Pseudounipolar lead for stimulating a digestive organ
US20060074458A1 (en) * 2001-05-01 2006-04-06 Imran Mir A Digestive organ retention device
US7509174B2 (en) 2001-05-01 2009-03-24 Intrapace, Inc. Gastric treatment/diagnosis device and attachment device and method
US7483754B2 (en) 2001-05-01 2009-01-27 Intrapace, Inc. Endoscopic instrument system for implanting a device in the stomach
US20060089699A1 (en) * 2001-05-01 2006-04-27 Imran Mir A Abdominally implanted stimulator and method
US20090018605A1 (en) * 2001-05-01 2009-01-15 Intrapace, Inc. Gastric Treatment/Diagnosis Device and Attachment Device and Method
US20060116735A1 (en) * 2001-05-01 2006-06-01 Imran Mir A Gastric device and endoscopic delivery system
US7076305B2 (en) 2001-05-01 2006-07-11 Intrapace, Inc. Gastric device and instrument system and method
US8190261B2 (en) 2001-05-01 2012-05-29 Intrapace, Inc. Gastrointestinal anchor in optimal surface area
US7107100B2 (en) 2001-05-01 2006-09-12 Intrapace, Inc. Aendoscopic instrument system@
US20030167024A1 (en) * 2001-05-01 2003-09-04 Imran Mir A. Gastric device and instrument system and method
US7120498B2 (en) 2001-05-01 2006-10-10 Intrapace, Inc. Method and device for securing a functional device to a stomach
US8239027B2 (en) 2001-05-01 2012-08-07 Intrapace, Inc. Responsive gastric stimulator
US8364269B2 (en) 2001-05-01 2013-01-29 Intrapace, Inc. Responsive gastric stimulator
US7371215B2 (en) 2001-05-01 2008-05-13 Intrapace, Inc. Endoscopic instrument for engaging a device
US20030144708A1 (en) * 2002-01-29 2003-07-31 Starkebaum Warren L. Methods and apparatus for retarding stomach emptying for treatment of eating disorders
US7236822B2 (en) 2002-03-22 2007-06-26 Leptos Biomedical, Inc. Wireless electric modulation of sympathetic nervous system
US20070219596A1 (en) * 2002-03-22 2007-09-20 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous sytem
US20030181958A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Electric modulation of sympathetic nervous system
US20100145408A1 (en) * 2002-03-22 2010-06-10 Dobak Iii John D Splanchnic Nerve Stimulation For Treatment of Obesity
US20100234907A1 (en) * 2002-03-22 2010-09-16 Dobak Iii John D Splanchnic Nerve Stimulation for Treatment of Obesity
US20040230255A1 (en) * 2002-03-22 2004-11-18 Dobak John D. Splanchnic nerve stimulation for treatment of obesity
US7702386B2 (en) 2002-03-22 2010-04-20 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US20100249889A1 (en) * 2002-03-22 2010-09-30 Dobak Iii John D Neural Stimulation For Treatment of Metabolic Syndrome and Type 2 Diabetes
US7689277B2 (en) 2002-03-22 2010-03-30 Leptos Biomedical, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US8145299B2 (en) 2002-03-22 2012-03-27 Advanced Neuromodulation Systems, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US8024035B2 (en) 2002-03-22 2011-09-20 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US7239912B2 (en) 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US20070203521A1 (en) * 2002-03-22 2007-08-30 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes
US8340760B2 (en) 2002-03-22 2012-12-25 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US20070225768A1 (en) * 2002-03-22 2007-09-27 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US8838231B2 (en) 2002-03-22 2014-09-16 Advanced Neuromodulation Systems, Inc. Neural Stimulation for treatment of metabolic syndrome and type 2 diabetes
US20090259279A1 (en) * 2002-03-22 2009-10-15 Dobak Iii John D Splanchnic nerve stimulation for treatment of obesity
US7937144B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US20080033511A1 (en) * 2002-03-22 2008-02-07 Leptos Biomedical, Inc. Dynamic nerve stimulation employing frequency modulation
US7937145B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation employing frequency modulation
US20060190053A1 (en) * 2002-03-22 2006-08-24 Dobak John D Iii Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US7551964B2 (en) 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US20030181959A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Wireless electric modulation of sympathetic nervous system
US20100331910A1 (en) * 2002-05-09 2010-12-30 Daemen College Electrical stimulation unit and waterbath system
US7837719B2 (en) 2002-05-09 2010-11-23 Daemen College Electrical stimulation unit and waterbath system
WO2003099376A1 (en) * 2002-05-23 2003-12-04 Transneuronix, Inc. Improved process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease
US20080183238A1 (en) * 2002-07-26 2008-07-31 Medtronic, Inc. Process for electrostimulation treatment of morbid obesity
US8845513B2 (en) 2002-08-13 2014-09-30 Apollo Endosurgery, Inc. Remotely adjustable gastric banding device
US8382780B2 (en) 2002-08-28 2013-02-26 Allergan, Inc. Fatigue-resistant gastric banding device
US7689276B2 (en) 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US20050065575A1 (en) * 2002-09-13 2005-03-24 Dobak John D. Dynamic nerve stimulation for treatment of disorders
US8538533B2 (en) 2003-02-03 2013-09-17 Enteromedics Inc. Controlled vagal blockage therapy
US20110034968A1 (en) * 2003-02-03 2011-02-10 Enteromedics Inc. Controlled vagal blockage therapy
US20040172086A1 (en) * 2003-02-03 2004-09-02 Beta Medical, Inc. Nerve conduction block treatment
US7729771B2 (en) 2003-02-03 2010-06-01 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7720540B2 (en) 2003-02-03 2010-05-18 Enteromedics, Inc. Pancreatitis treatment
US9174040B2 (en) 2003-02-03 2015-11-03 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US20070135857A1 (en) * 2003-02-03 2007-06-14 Enteromedics, Inc. GI inflammatory disease treatment
US8046085B2 (en) 2003-02-03 2011-10-25 Enteromedics Inc. Controlled vagal blockage therapy
US7489969B2 (en) 2003-02-03 2009-02-10 Enteromedics Inc. Vagal down-regulation obesity treatment
US20070135858A1 (en) * 2003-02-03 2007-06-14 Enteromedics, Inc. Pancreatitis treatment
US20050131485A1 (en) * 2003-02-03 2005-06-16 Enteromedics, Inc. High frequency vagal blockage therapy
US9586046B2 (en) 2003-02-03 2017-03-07 Enteromedics, Inc. Electrode band system and methods of using the system to treat obesity
US9682233B2 (en) 2003-02-03 2017-06-20 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US8010204B2 (en) 2003-02-03 2011-08-30 Enteromedics Inc. Nerve blocking for treatment of gastrointestinal disorders
US7630769B2 (en) 2003-02-03 2009-12-08 Enteromedics Inc. GI inflammatory disease treatment
US20070135846A1 (en) * 2003-02-03 2007-06-14 Enteromedics, Inc. Vagal obesity treatment
US7693577B2 (en) 2003-02-03 2010-04-06 Enteromedics Inc. Irritable bowel syndrome treatment
US20070135856A1 (en) * 2003-02-03 2007-06-14 Enteromedics, Inc. Bulimia treatment
US9162062B2 (en) 2003-02-03 2015-10-20 Enteromedics Inc. Controlled vagal blockage therapy
US8862233B2 (en) 2003-02-03 2014-10-14 Enteromedics Inc. Electrode band system and methods of using the system to treat obesity
US8369952B2 (en) 2003-02-03 2013-02-05 Enteromedics, Inc. Bulimia treatment
US8538542B2 (en) 2003-02-03 2013-09-17 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US20070142870A1 (en) * 2003-02-03 2007-06-21 Enteromedics, Inc. Irritable bowel syndrome treatment
US20060229685A1 (en) * 2003-02-03 2006-10-12 Knudson Mark B Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US7986995B2 (en) 2003-02-03 2011-07-26 Enteromedics Inc. Bulimia treatment
US20080021512A1 (en) * 2003-02-03 2008-01-24 Enteromedics Inc. Nerve stimulation and blocking for treatment of gastrointestinal disorders
US20050038484A1 (en) * 2003-02-03 2005-02-17 Enteromedics, Inc. Controlled vagal blockage therapy
US20040267330A1 (en) * 2003-04-25 2004-12-30 Lee Michael T. Generation of theraphy programs and program groups
US7826901B2 (en) 2003-04-25 2010-11-02 Medtronic, Inc. Generation of therapy programs and program groups
US20070123953A1 (en) * 2003-04-25 2007-05-31 Medtronic, Inc. Generation of therapy programs and program groups
US8068915B2 (en) 2003-04-25 2011-11-29 Medtronic, Inc. Generation of therapy programs and program groups
US20140072929A1 (en) * 2003-06-19 2014-03-13 Osstell Ab Method and arrangement relating to testing objects
US7430450B2 (en) 2003-10-22 2008-09-30 Intrapace, Inc. Device and method for treating obesity
US20100286745A1 (en) * 2003-10-22 2010-11-11 Intrapace, Inc. Radially Expandable Gastrointestinal Stimulation Device
US7676270B2 (en) 2003-10-22 2010-03-09 Intrapace, Inc. Radially expandable gastrointestinal stimulation device
US20050090873A1 (en) * 2003-10-22 2005-04-28 Imran Mir A. Gastrointestinal stimulation device
US7054690B2 (en) 2003-10-22 2006-05-30 Intrapace, Inc. Gastrointestinal stimulation device
US7343201B2 (en) * 2003-11-28 2008-03-11 University Technologies International Inc. Gastrointestinal motility control
US9050464B2 (en) 2003-11-28 2015-06-09 Uti Limited Partnership Gastrointestinal motility control
US20050137643A1 (en) * 2003-11-28 2005-06-23 Mintchev Martin P. Gastrointestinal motility control
US8706231B2 (en) 2003-11-28 2014-04-22 University Technologies International Inc. Gastrointestinal motility control
US20080200964A1 (en) * 2003-11-28 2008-08-21 University Technologies International Inc. Gastrointestinal motility control
US20050128187A1 (en) * 2003-12-12 2005-06-16 Yu-Yu Chen Computer cursor pointing device with electric stimulator
US7193611B2 (en) * 2003-12-12 2007-03-20 Yu-Yu Chen Computer cursor pointing device with electric stimulator
US7177693B2 (en) 2004-01-07 2007-02-13 Medtronic, Inc. Gastric stimulation for altered perception to treat obesity
US20050149141A1 (en) * 2004-01-07 2005-07-07 Starkebaum Warren L. Gastric stimulation for altered perception to treat obesity
US8900117B2 (en) 2004-01-23 2014-12-02 Apollo Endosurgery, Inc. Releasably-securable one-piece adjustable gastric band
US20050187597A1 (en) * 2004-02-25 2005-08-25 Vanderschuit Carl R. Therapeutic devices and methods for applying therapy
US8377081B2 (en) 2004-03-08 2013-02-19 Allergan, Inc. Closure system for tubular organs
US8236023B2 (en) 2004-03-18 2012-08-07 Allergan, Inc. Apparatus and method for volume adjustment of intragastric balloons
US20050222638A1 (en) * 2004-03-30 2005-10-06 Steve Foley Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders
US20050222637A1 (en) * 2004-03-30 2005-10-06 Transneuronix, Inc. Tachygastrial electrical stimulation
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US20060036293A1 (en) * 2004-08-16 2006-02-16 Whitehurst Todd K Methods for treating gastrointestinal disorders
US8452407B2 (en) 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
US7623924B2 (en) 2004-08-31 2009-11-24 Leptos Biomedical, Inc. Devices and methods for gynecologic hormone modulation in mammals
US9662240B2 (en) 2004-09-23 2017-05-30 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors
US8934976B2 (en) 2004-09-23 2015-01-13 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors
US9259342B2 (en) 2004-09-23 2016-02-16 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors
US20060070334A1 (en) * 2004-09-27 2006-04-06 Blue Hen, Llc Sidewall plank for constructing a trailer and associated trailer sidewall construction
US8251888B2 (en) 2005-04-13 2012-08-28 Mitchell Steven Roslin Artificial gastric valve
US20100274274A1 (en) * 2005-04-13 2010-10-28 Allergan, Inc. Artificial gastric valve
US20060235448A1 (en) * 2005-04-13 2006-10-19 Roslin Mitchell S Artificial gastric valve
US8623042B2 (en) 2005-04-13 2014-01-07 Mitchell Roslin Artificial gastric valve
US8761888B2 (en) * 2005-07-29 2014-06-24 Medtronic, Inc. Transmembrane sensing device for sensing bladder condition
US20110190844A1 (en) * 2005-07-29 2011-08-04 Medtronic, Inc. Transmembrane sensing device for sensing bladder condition
US7672727B2 (en) 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US20100094375A1 (en) * 2005-08-17 2010-04-15 Enteromedics Inc. Neural electrode treatment
US8103349B2 (en) 2005-08-17 2012-01-24 Enteromedics Inc. Neural electrode treatment
US20070043411A1 (en) * 2005-08-17 2007-02-22 Enteromedics Inc. Neural electrode
US20070043400A1 (en) * 2005-08-17 2007-02-22 Donders Adrianus P Neural electrode treatment
US8032223B2 (en) 2005-09-01 2011-10-04 Intrapace, Inc. Randomized stimulation of a gastrointestinal organ
US20070049986A1 (en) * 2005-09-01 2007-03-01 Imran Mir A Randomized stimulation of a gastrointestinal organ
US7616996B2 (en) 2005-09-01 2009-11-10 Intrapace, Inc. Randomized stimulation of a gastrointestinal organ
US20100023087A1 (en) * 2005-09-01 2010-01-28 Intrapace, Inc. Randomized stimulation of a gastrointestinal organ
US20070078494A1 (en) * 2005-09-23 2007-04-05 Mintchev Martin P Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity
US20090018606A1 (en) * 2005-10-12 2009-01-15 Intrapace, Inc. Methods and Devices for Stimulation of an Organ with the Use of a Transectionally Placed Guide Wire
CN100469401C (en) * 2005-10-28 2009-03-18 清华大学 Implant nervous electric pulse stimulus system
US20090234417A1 (en) * 2005-11-10 2009-09-17 Electrocore, Inc. Methods And Apparatus For The Treatment Of Metabolic Disorders
US8323180B2 (en) 2006-01-04 2012-12-04 Allergan, Inc. Hydraulic gastric band with collapsible reservoir
US8308630B2 (en) 2006-01-04 2012-11-13 Allergan, Inc. Hydraulic gastric band with collapsible reservoir
US8905915B2 (en) 2006-01-04 2014-12-09 Apollo Endosurgery, Inc. Self-regulating gastric band with pressure data processing
US8630715B2 (en) 2006-04-12 2014-01-14 Medtronic, Inc. Rule-based stimulation program search
US20090157138A1 (en) * 2006-04-18 2009-06-18 Electrocore, Inc. Methods And Apparatus For Treating Ileus Condition Using Electrical Signals
US20100057178A1 (en) * 2006-04-18 2010-03-04 Electrocore, Inc. Methods and apparatus for spinal cord stimulation using expandable electrode
US7558629B2 (en) * 2006-04-28 2009-07-07 Medtronic, Inc. Energy balance therapy for obesity management
US20070255334A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Energy balance therapy for obesity management
US20070255154A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Activity level feedback for managing obesity
US8185206B2 (en) 2006-05-17 2012-05-22 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
US20070282387A1 (en) * 2006-05-17 2007-12-06 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
WO2007136712A3 (en) * 2006-05-17 2008-02-21 Medtronic Inc Electrical stimulation therapy to promote gastric distention for obesity management
US8295926B2 (en) 2006-06-02 2012-10-23 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US20080262411A1 (en) * 2006-06-02 2008-10-23 Dobak John D Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US7894906B2 (en) 2006-06-06 2011-02-22 Cardiac Pacemakers, Inc. Amelioration of chronic pain by endolymphatic stimulation
US8897878B2 (en) 2006-06-06 2014-11-25 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US20070282386A1 (en) * 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for gastrointestinal stimulation via the lymphatic system
US20100217346A1 (en) * 2006-06-06 2010-08-26 Shuros Allan C Method and apparatus for gastrointestinal stimulation via the lymphatic system
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US8126538B2 (en) 2006-06-06 2012-02-28 Cardiac Pacemakers, Inc. Method and apparatus for introducing endolymphatic instrumentation
US20070282390A1 (en) * 2006-06-06 2007-12-06 Shuros Allan C Amelioration of chronic pain by endolymphatic stimulation
US20080009719A1 (en) * 2006-06-06 2008-01-10 Shuros Allan C Method and apparatus for introducing endolymphatic instrumentation
US8369943B2 (en) 2006-06-06 2013-02-05 Cardiac Pacemakers, Inc. Method and apparatus for neural stimulation via the lymphatic system
US7509175B2 (en) 2006-08-03 2009-03-24 Intrapace, Inc. Method and devices for stimulation of an organ with the use of a transectionally placed guide wire
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
US20080097412A1 (en) * 2006-09-01 2008-04-24 Shuros Allan C Method and apparatus for endolymphatic drug delivery
US20080195171A1 (en) * 2007-02-13 2008-08-14 Sharma Virender K Method and Apparatus for Electrical Stimulation of the Pancreatico-Biliary System
US9037244B2 (en) 2007-02-13 2015-05-19 Virender K. Sharma Method and apparatus for electrical stimulation of the pancreatico-biliary system
US20080281365A1 (en) * 2007-05-09 2008-11-13 Tweden Katherine S Neural signal duty cycle
US20080294228A1 (en) * 2007-05-23 2008-11-27 Cardiac Pacemakers Method and device for controlled stimulation of lymphatic flow
US20090030474A1 (en) * 2007-06-29 2009-01-29 Intrapace, Inc. Sensor Driven Gastric Stimulation for Patient Management
US8214049B2 (en) 2007-07-25 2012-07-03 Intrapace Inc. Gastric stimulation systems and methods utilizing a transgastric probe
US20090030475A1 (en) * 2007-07-25 2009-01-29 Intrapace, Inc. Gastric Stimulation Systems and Methods Utilizing a Transgastric Probe
US20090118777A1 (en) * 2007-08-09 2009-05-07 Kobi Iki Efferent and afferent splanchnic nerve stimulation
US20090088819A1 (en) * 2007-10-01 2009-04-02 Medtronic, Inc. Gastric electrical stimulation with multi-site stimulation anti-desensitization feature
US7983755B2 (en) 2007-10-01 2011-07-19 Medtronic, Inc. Gastric electrical stimulation with multi-site stimulation anti-desensitization feature
US20090088817A1 (en) * 2007-10-01 2009-04-02 Medtronic, Inc. Gastric electrical stimulation with lockout interval anti-desensitization feature
US9446234B2 (en) * 2007-10-01 2016-09-20 Medtronic, Inc. Gastric electrical stimulation with lockout interval anti-desensitization feature
US8292800B2 (en) 2008-06-11 2012-10-23 Allergan, Inc. Implantable pump system
US20090312785A1 (en) * 2008-06-11 2009-12-17 Allergan, Inc. Implantable Pump System
US20100076508A1 (en) * 2008-09-25 2010-03-25 Boston Scientific Neuromodulation Corporation Electrical stimulation leads having rf compatibility and methods of use and manufacture
US8364279B2 (en) 2008-09-25 2013-01-29 Boston Scientific Neuromodulation Corporation Electrical stimulation leads having RF compatibility and methods of use and manufacture
US8483844B2 (en) 2008-09-25 2013-07-09 Boston Scientific Neuromodulation Corporation Electrical stimulation leads having RF compatibility and methods of use and manufacture
US8317677B2 (en) 2008-10-06 2012-11-27 Allergan, Inc. Mechanical gastric band with cushions
US11517749B2 (en) 2008-10-09 2022-12-06 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
US10376694B2 (en) 2008-10-09 2019-08-13 Virender K. Sharma Method and apparatus for stimulating the vascular system
US8900118B2 (en) 2008-10-22 2014-12-02 Apollo Endosurgery, Inc. Dome and screw valves for remotely adjustable gastric banding systems
US20100324611A1 (en) * 2008-12-10 2010-12-23 Waverx, Inc. Devices, systems and methods for preventing and treating sensation loss
US20100160745A1 (en) * 2008-12-12 2010-06-24 Intrapace, Inc. Detection of Food or Drink Consumption In Order to Control Therapy or Provide Diagnostics
US20100268297A1 (en) * 2009-02-24 2010-10-21 Hans Neisz Duodenal Stimulation To Induce Satiety
US8538532B2 (en) 2009-03-03 2013-09-17 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
US20100228313A1 (en) * 2009-03-03 2010-09-09 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
US8715181B2 (en) 2009-04-03 2014-05-06 Intrapace, Inc. Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments
EP2414032A4 (en) * 2009-04-03 2016-08-10 Intrapace Inc Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments
US20110034760A1 (en) * 2009-04-03 2011-02-10 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments
US20110087076A1 (en) * 2009-04-03 2011-04-14 Intrapace, Inc. Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
US8340772B2 (en) 2009-05-08 2012-12-25 Advanced Neuromodulation Systems, Inc. Brown adipose tissue utilization through neuromodulation
US9937344B2 (en) 2009-09-21 2018-04-10 Medtronic, Inc. Waveforms for electrical stimulation therapy
US20110071589A1 (en) * 2009-09-21 2011-03-24 Medtronic, Inc. Waveforms for electrical stimulation therapy
US20110201874A1 (en) * 2010-02-12 2011-08-18 Allergan, Inc. Remotely adjustable gastric banding system
US8678993B2 (en) 2010-02-12 2014-03-25 Apollo Endosurgery, Inc. Remotely adjustable gastric banding system
US20110201875A1 (en) * 2010-02-12 2011-08-18 Allergan, Inc. Remotely adjustable gastric banding system
US8758221B2 (en) 2010-02-24 2014-06-24 Apollo Endosurgery, Inc. Source reservoir with potential energy for remotely adjustable gastric banding system
US8764624B2 (en) 2010-02-25 2014-07-01 Apollo Endosurgery, Inc. Inductively powered remotely adjustable gastric banding system
US8840541B2 (en) 2010-02-25 2014-09-23 Apollo Endosurgery, Inc. Pressure sensing gastric banding system
US20110257760A1 (en) * 2010-04-15 2011-10-20 Waldrep Donald J Gastric implant and method for use of same
US20150351944A1 (en) * 2010-04-15 2015-12-10 Donald J. Waldrep Gastric implant and method for use of same
US9295573B2 (en) 2010-04-29 2016-03-29 Apollo Endosurgery, Inc. Self-adjusting gastric band having various compliant components and/or a satiety booster
US9044298B2 (en) 2010-04-29 2015-06-02 Apollo Endosurgery, Inc. Self-adjusting gastric band
US9028394B2 (en) 2010-04-29 2015-05-12 Apollo Endosurgery, Inc. Self-adjusting mechanical gastric band
US9192501B2 (en) 2010-04-30 2015-11-24 Apollo Endosurgery, Inc. Remotely powered remotely adjustable gastric band system
US9226840B2 (en) 2010-06-03 2016-01-05 Apollo Endosurgery, Inc. Magnetically coupled implantable pump system and method
US8517915B2 (en) 2010-06-10 2013-08-27 Allergan, Inc. Remotely adjustable gastric banding system
US9358395B2 (en) 2010-06-11 2016-06-07 Enteromedics Inc. Neural modulation devices and methods
US9968778B2 (en) 2010-06-11 2018-05-15 Reshape Lifesciences Inc. Neural modulation devices and methods
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US9211207B2 (en) 2010-08-18 2015-12-15 Apollo Endosurgery, Inc. Power regulated implant
US8698373B2 (en) 2010-08-18 2014-04-15 Apollo Endosurgery, Inc. Pare piezo power with energy recovery
US9050165B2 (en) 2010-09-07 2015-06-09 Apollo Endosurgery, Inc. Remotely adjustable gastric banding system
US8961393B2 (en) 2010-11-15 2015-02-24 Apollo Endosurgery, Inc. Gastric band devices and drive systems
US8876694B2 (en) 2011-12-07 2014-11-04 Apollo Endosurgery, Inc. Tube connector with a guiding tip
US8961394B2 (en) 2011-12-20 2015-02-24 Apollo Endosurgery, Inc. Self-sealing fluid joint for use with a gastric band
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9950171B2 (en) 2014-10-31 2018-04-24 Medtronic, Inc. Paired stimulation pulses based on sensed compound action potential

Also Published As

Publication number Publication date
CA2421846A1 (en) 2002-04-04
WO2002026317A8 (en) 2002-07-11
NO20031348D0 (en) 2003-03-25
CN1476339A (en) 2004-02-18
AU2001293039A1 (en) 2002-04-08
EP1322380A4 (en) 2009-06-03
NO20031348L (en) 2003-05-23
EP1322380A1 (en) 2003-07-02
WO2002026317A1 (en) 2002-04-04
US20040162595A1 (en) 2004-08-19
JP2004509714A (en) 2004-04-02
US7941221B2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
US7941221B2 (en) Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US6091992A (en) Method and apparatus for electrical stimulation of the gastrointestinal tract
EP1357971B1 (en) Regulation of eating habits
US6615084B1 (en) Process for electrostimulation treatment of morbid obesity
US8494637B2 (en) Systems and methods for implantable leadless gastrointestinal tissue stimulation
US10376694B2 (en) Method and apparatus for stimulating the vascular system
US20080086180A1 (en) Techniques for gall bladder stimulation
US9037244B2 (en) Method and apparatus for electrical stimulation of the pancreatico-biliary system
US5716385A (en) Crural diaphragm pacemaker and method for treating esophageal reflux disease
US6115635A (en) Method and apparatus for electrical stimulation of the gastrointestinal tract
US7738961B2 (en) Method and apparatus for treatment of the gastrointestinal tract
US5540730A (en) Treatment of motility disorders by nerve stimulation
US20040193229A1 (en) Gastric electrical stimulation for treatment of gastro-esophageal reflux disease
US20030144708A1 (en) Methods and apparatus for retarding stomach emptying for treatment of eating disorders
US20080132962A1 (en) System and method for affecting gatric functions
US20040015201A1 (en) Process for electrostimulation treatment of obesity
WO1999003532A2 (en) Apparatus for treatment of gastric arrhythmias
US20070078494A1 (en) Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity
Lönroth et al. Laparoscopic and open placement of electronic implants for gastric electrical stimulation (GES): technique and results

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRANSNEURONIX, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOLEY, STEPHEN T.;REEL/FRAME:012537/0740

Effective date: 20011211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION